
<html lang="en"     class="pb-page"  data-request-id="be2c56f9-8f14-4ad8-b099-28e88095e215"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00267;issue:issue:10.1021/jmcmar.2017.60.issue-8;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point" /></meta><meta name="dc.Creator" content="Richard A.  Ward" /></meta><meta name="dc.Creator" content="Paul  Bethel" /></meta><meta name="dc.Creator" content="Calum  Cook" /></meta><meta name="dc.Creator" content="Emma  Davies" /></meta><meta name="dc.Creator" content="Judit E.  Debreczeni" /></meta><meta name="dc.Creator" content="Gary  Fairley" /></meta><meta name="dc.Creator" content="Lyman  Feron" /></meta><meta name="dc.Creator" content="Vikki  Flemington" /></meta><meta name="dc.Creator" content="Mark A.  Graham" /></meta><meta name="dc.Creator" content="Ryan  Greenwood" /></meta><meta name="dc.Creator" content="Nicola  Griffin" /></meta><meta name="dc.Creator" content="Lyndsey  Hanson" /></meta><meta name="dc.Creator" content="Philip  Hopcroft" /></meta><meta name="dc.Creator" content="Tina D.  Howard" /></meta><meta name="dc.Creator" content="Julian  Hudson" /></meta><meta name="dc.Creator" content="Michael  James" /></meta><meta name="dc.Creator" content="Clifford D.  Jones" /></meta><meta name="dc.Creator" content="Christopher R.  Jones" /></meta><meta name="dc.Creator" content="Scott  Lamont" /></meta><meta name="dc.Creator" content="Richard  Lewis" /></meta><meta name="dc.Creator" content="Nicola  Lindsay" /></meta><meta name="dc.Creator" content="Karen  Roberts" /></meta><meta name="dc.Creator" content="Iain  Simpson" /></meta><meta name="dc.Creator" content="Steve  St-Gallay" /></meta><meta name="dc.Creator" content="Steve  Swallow" /></meta><meta name="dc.Creator" content="Jia  Tang" /></meta><meta name="dc.Creator" content="Michael  Tonge" /></meta><meta name="dc.Creator" content="Zhenhua  Wang" /></meta><meta name="dc.Creator" content="Baochang  Zhai" /></meta><meta name="dc.Description" content="There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease ..." /></meta><meta name="Description" content="There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 14, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00267" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00267" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00267" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00267" /></link>
        
    
    

<title>Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00267" /></meta><meta property="og:title" content="Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0017.jpeg" /></meta><meta property="og:description" content="There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound 4. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound 35, which was active when tested in in vivo antitumor efficacy experiments." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00267"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00267">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00267&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00267&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00267&amp;href=/doi/10.1021/acs.jmedchem.7b00267" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3438-3450</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00241" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00295" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Ward">Richard A. Ward</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2310-9477" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Bethel">Paul Bethel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Calum++Cook">Calum Cook</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emma++Davies">Emma Davies</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judit+E.++Debreczeni">Judit E. Debreczeni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Fairley">Gary Fairley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lyman++Feron">Lyman Feron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vikki++Flemington">Vikki Flemington</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Graham">Mark A. Graham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Greenwood">Ryan Greenwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Griffin">Nicola Griffin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lyndsey++Hanson">Lyndsey Hanson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Hopcroft">Philip Hopcroft</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tina+D.++Howard">Tina D. Howard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julian++Hudson">Julian Hudson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++James">Michael James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clifford+D.++Jones">Clifford D. Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+R.++Jones">Christopher R. Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>△</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Lamont">Scott Lamont</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Lewis">Richard Lewis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Lindsay">Nicola Lindsay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Roberts">Karen Roberts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Iain++Simpson">Iain Simpson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++St-Gallay">Steve St-Gallay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>¶</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Swallow">Steve Swallow</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Tang">Jia Tang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Tonge">Michael Tonge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenhua++Wang">Zhenhua Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Baochang++Zhai">Baochang Zhai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">IMED Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">∥</span> <span class="aff-text">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P.R. China</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#11637872797063753f703f667063755170626563706b747f7472703f727e7c"><span class="__cf_email__" data-cfemail="a4d6cdc7ccc5d6c08ac58ad3c5d6c0e4c5d7d0d6c5dec1cac1c7c58ac7cbc9">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00267&amp;href=/doi/10.1021%2Facs.jmedchem.7b00267" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3438–3450</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 4, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 February 2017</li><li><span class="item_label"><b>Published</b> online</span>14 April 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00267" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00267</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3438%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BA.%2BWard%252C%2BPaul%2BBethel%252C%2BCalum%2BCook%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D8%26contentID%3Dacs.jmedchem.7b00267%26title%3DStructure-Guided%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BInhibitors%2Bof%2BERK1%252F2%2Bfrom%2Ba%2BModestly%2BActive%2Band%2BPromiscuous%2BChemical%2BStart%2BPoint%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3450%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00267"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3195</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00267" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Ward&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Bethel&quot;},{&quot;first_name&quot;:&quot;Calum&quot;,&quot;last_name&quot;:&quot;Cook&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;Davies&quot;},{&quot;first_name&quot;:&quot;Judit&quot;,&quot;last_name&quot;:&quot;E. Debreczeni&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Fairley&quot;},{&quot;first_name&quot;:&quot;Lyman&quot;,&quot;last_name&quot;:&quot;Feron&quot;},{&quot;first_name&quot;:&quot;Vikki&quot;,&quot;last_name&quot;:&quot;Flemington&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Graham&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Greenwood&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Griffin&quot;},{&quot;first_name&quot;:&quot;Lyndsey&quot;,&quot;last_name&quot;:&quot;Hanson&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Hopcroft&quot;},{&quot;first_name&quot;:&quot;Tina&quot;,&quot;last_name&quot;:&quot;D. Howard&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;Hudson&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Clifford&quot;,&quot;last_name&quot;:&quot;D. Jones&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;R. Jones&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Lamont&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Lindsay&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Roberts&quot;},{&quot;first_name&quot;:&quot;Iain&quot;,&quot;last_name&quot;:&quot;Simpson&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;St-Gallay&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Swallow&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Tonge&quot;},{&quot;first_name&quot;:&quot;Zhenhua&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Baochang&quot;,&quot;last_name&quot;:&quot;Zhai&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;3438-3450&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00267&quot;},&quot;abstract&quot;:&quot;There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound 4. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound 35, which was active when tested in in vivo antitumor efficacy experiments.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00267&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00267" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00267&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00267" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00267&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00267" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00267&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00267&amp;href=/doi/10.1021/acs.jmedchem.7b00267" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00267" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00267" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00267%26sid%3Dliteratum%253Aachs%26pmid%3D28376306%26genre%3Darticle%26aulast%3DWard%26date%3D2017%26atitle%3DStructure-Guided%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BInhibitors%2Bof%2BERK1%252F2%2Bfrom%2Ba%2BModestly%2BActive%2Band%2BPromiscuous%2BChemical%2BStart%2BPoint%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D8%26spage%3D3438%26epage%3D3450%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292580" title="Binding modes">Binding modes</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/jmcmar.2017.60.issue-8/20170427/jmcmar.2017.60.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound <b>4</b>. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound <b>35</b>, which was active when tested in in vivo antitumor efficacy experiments.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The MAPK (RAS/RAF/MEK/ERK) pathway plays a central role in controlling mammalian cell cycle progression, differentiation, protein synthesis, metabolism, survival, migration, and senescence. This pathway is activated by a wide range of receptors, including receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), and cytokine receptors, which results in activation of the RAS family of GTPases (KRAS, NRAS, and HRAS). Subsequently, signals are transmitted downstream through RAF (BRAF, CRAF, and ARAF) and MEK (MEK1 and MEK2) protein kinases. MEK1 and MEK2 are dual-specificity kinases that activate ERK1 and ERK2 via the phosphorylation of conserved threonine and tyrosine residues in the T-E-Y motif located within the activation loop. ERK1 and ERK2 control the output of the MAPK pathway by activating their many substrates, both nuclear and cytoplasmic.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Direct phosphorylation of transcription factors induces extensive changes in gene expression that promote cell cycle progression and regulate negative feedback mechanisms. The activation of the MAPK pathway is also impacted by scaffold proteins such as kinase suppressor of RAS 1 (KSR1), which increase the efficiency of the interactions between the enzyme and substrate at each step. The high frequency of mutations resulting in constitutive activation of the MAPK pathway provides a strong rationale for pharmacologically inhibiting the pathway. Mutations in BRAF have been identified in melanoma (60%), thyroid (∼50%), and colorectal (10%) tumors,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> whereas RAS genes are mutated in colorectal (50%), melanoma (20%), and pancreatic (90%) tumors. Small-molecule inhibitors targeting BRAF and MEK have been developed and have subsequently been approved in multiple disease indications.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> BRAF inhibitors such as vemurafenib and dabrafenib demonstrate dramatic regression of melanomas carrying the BRAF V600E mutation,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> whereas BRAF wild-type tumors are refractory. However, acquired resistance to BRAF inhibitors occurs in a significant subset of patients, primarily from genetic alterations resulting in MAPK pathway reactivation.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> In melanoma, BRAF inhibitor monotherapy is now superseded by BRAF plus MEK inhibitor combinations,<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> although acquired resistance resulting in patient relapse remains an issue. In addition, several selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have also been developed and assessed in multiple clinical trials, with trametinib having been approved by the U.S. Food and Drug Administration. Efficacy as single-agent therapy has been reported with MEK inhibitors in clinical settings such as BRAF mutant melanoma and serous low-grade ovarian cancer,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> but there are limited data on monotherapy responses in other settings.</div><div class="NLM_p">Direct targeting of ERK1/2, the key signaling node of the MAPK pathway, may provide another therapeutic option in tumors with mutations in BRAF or RAS genes. Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors where MAPK pathway reactivation has occurred, such as BRAF mutant melanoma. ERK1 and ERK2 are 85% identical by sequence (significantly higher in the ATP binding site) and share some, if not all, of their functions with reported inhibitors assumed to be active against both. A range of small-molecule reversible ERK1/2 inhibitors have been disclosed, including compounds such as <b>1</b> (SCH772984),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><b>2</b> (BVD-523),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and <b>3</b> (GDC-0994)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). There are also a number of reported clinical and preclinical inhibitors without chemical structures revealed, including inhibitors from Celgene,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Novartis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Kura Oncology,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and Eli Lilly.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, we have reported a series of highly selective covalent ERK1/2 inhibitors<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> using structure-based drug design. However, some trials involving ERK1/2 inhibitors have recently been stopped or are no longer recruiting participants.<a onclick="showRef(event, 'ref14 ref19'); return false;" href="javascript:void(0);" class="ref ref14 ref19">(14, 19)</a> Therefore, the identification of high-quality, potent, and selective inhibitors of ERK1/2 remains of great interest within oncology drug discovery, and this paper details our recent research efforts toward this aim.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of published ERK1/2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Series Identification</h3><div class="NLM_p">A number of hit identification approaches were considered in our efforts to identify high-quality, potent, and selective reversible inhibitors of ERK1/2 with good physicochemical properties. In one approach, we mined our historic kinase selectivity data from previous drug discovery projects to identify compounds with activity against ERK1 or ERK2. This analysis provided relatively few active compounds, but a small number of hits were followed-up and tested in an ERK2 biochemical assay (run at 60 μM (<i>K</i><sub>M</sub>) ATP) to confirm and quantify the potency. Example <b>4</b>, with a pyrimidine–pyrrololactam core, appeared to be the most interesting inhibitor, with an activity of 0.036 μM and relatively low molecular weight and log <i>D</i>, giving scope for further development (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Further testing of this compound included 1 mM ATP conditions in the biochemical assay to mimic cellular levels of ATP. In addition, a mechanism of action (MOA) cell assay measuring levels of phosphorylated ERK2 (pERK) and of the phosphorylation of the downstream kinase RSK (pRSK) was performed in an A375 melanoma cell line containing a BRAF<sup>V600E</sup> mutation. The active concentration of ERK2 used in the biochemical assays was determined by fitting compound inhibition data to the Morrison equation. This gave an active enzyme concentration of 0.6 nM and a tight-binding limit of 0.3 nM for both assays.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The drop-off due to increased ATP competition was calculated using the Cheng–Prusoff equation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of our observed <i>K</i><sub>M</sub> of ERK for ATP (60 μM) and the assumption that the compounds are fully competitive with ATP, we anticipated an 8.8-fold drop-off from the <i>K</i><sub>M</sub> ATP assay to the 1 mM ATP assay. The biochemical activity of <b>4</b> was consistent with ATP-competitive behavior, showing an approximately 10-fold drop-off when an ATP concentration of 1 M was used. An additional observation, however, was the smaller than expected enzyme-to-cell drop-off, which was potentially due to off-target kinase activity, as our previous work had indicated that a significantly larger enzyme-to-cell drop-off was expected for selective reversible ERK1/2 inhibitors. For example, <b>2</b> demonstrated high ATP biochemical activity of <0.0003 μM, with pRSK MOA cell activity of 0.14 μM.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> To further characterize this risk, the kinase selectivity profile (Eurofins Millipore assays) was generated and showed broad kinase activity, with 75 out of a 128 kinase panel being >80% inhibited at a compound concentration of 1 μM (Figure S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">Supporting Information</a>). While not conclusive, these results were supportive that off-target kinase activity might contribute to the cellular activity of <b>4</b>. As we highlighted in our previous disclosure,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Eurofins assays for RAF and MEK1 are coupled assays, and therefore, compounds active in ERK1/2 may also appear active against RAF and MEK1. The MEK1 assay contains unactivated ERK2, with the CRAF assay containing unactivated MEK1 and ERK2. In-house biochemical testing was subsequently carried out to ensure that these compounds were not active against MEK1. Apart from <b>4</b> (IC<sub>50</sub> = 1.9 μM vs MEK), all of the other compounds in this article have IC<sub>50</sub> > 10 μM against MEK1.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Profile of Hit Compound <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0011.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left">0.036</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">0.16/0.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">189</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn0"><div class="footnote" id="t1fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements.</p></div><div class="footnote" id="t1fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t1fn2"><sup>c</sup><p class="last">Solubility of <b>4</b> in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t1fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Assessment of the Binding Mode of Hit Compound <b>4</b></h3><div class="NLM_p">In an effort to improve the potency and kinase selectivity of <b>4</b>, it was soaked in our ERK2 X-ray crystal structure system (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The binding mode was successfully identified and showed that the pyrimidine group forms a key interaction with the kinase hinge region (hydrogen bond to the backbone amide of Met-108), with the amide group of the pyrrololactam interacting with the conserved salt bridge (Lys-54 and Glu-71). We had expected to observe an additional interaction of the carbonyl with a bound water molecule, consistent with the interaction observed in our covalent ERK1/2 inhibitors,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> but such a water molecule may not be visible at this resolution (2.74 Å). The anilino group interacts with the hinge region as a hydrogen-bond donor to the backbone carbonyl of Met-108, and the piperidine group is directed into the “solvent channel” of the kinase. In an effort to understand how to improve the ERK potency and selectivity, the binding mode was compared with those of published ERK1/2 inhibitors, such as those reported by Aronov et al.;<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> an illustrative example with (<i>S</i>)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-<i>N</i>-(2-hydroxy-1-phenylethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>5</b>)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> is shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. From this analysis, we believed that we could improve the potency and selectivity both by modulating the group positioned in the “solvent channel” of the kinase and by extending our inhibitor into the glycine-rich loop region, contacting amino acids such as Tyr-36, Gly34, and Ile-56. Interestingly, without a group with which to interact in this region, Tyr-36 folds back into the ATP pocket, which appears to restrict access to the glycine-rich loop pocket, consistent with observations by Chaikuad et al.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> It was also a concern to us that the direct interaction of the amide group of the pyrrololactam with the conserved salt bridge might have a negative influence on the kinase selectivity. An additional interaction of compounds such as <b>5</b> reported by Aronov et al.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (and a number of other ERK1/2 inhibitors such as <b>2</b> and <b>3</b>) was the interaction of a hydrogen-bonding group, usually a hydroxyl, with Asp-165 and Asn-152, offering the potential to improve the potency while favorably modulating the physicochemical properties.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (top) Binding mode of <b>4</b> elucidated in the human ERK2 crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU">5NGU</a>). (middle) Binding mode of published inhibitor <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I60">3I60</a>). (bottom) Overlay of the structures of inhibitors <b>4</b> and <b>5</b>. This and similar figures were prepared using Schrödinger Maestro, version 2016-3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has previously been reported by Blake et al.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> that the addition of a tetrahydropyran (THP) group in the solvent channel on an anilinopyrimidine core enhances the kinase selectivity, which was rationalized by the interaction with Lys-114.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a><b>6</b> was synthesized to test whether this hypothesis transferred to our identified pyrrololactam core (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The data generated were consistent in terms of demonstrating improved biochemical potency (IC<sub>50</sub> = 0.001 μM) and kinase selectivity (14/128 kinases with >80% inhibition at 1 μM). A decrease in terms of cellular activity was observed (0.94 vs 0.57 μM in the pRSK MOA assay), but we rationalized this by the more selective nature of <b>6</b>, providing further evidence that off-target kinase activity contributes to the cellular activity of <b>4</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Early SAR around the Pyrimidine–Pyrrololactam Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0012.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>7</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center"><b>11</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left">0.0012</td><td class="colsep0 rowsep0" align="left">0.013</td><td class="colsep0 rowsep0" align="left"><0.00032</td><td class="colsep0 rowsep0" align="left"><0.00034</td><td class="colsep0 rowsep0" align="left"><0.00031</td><td class="colsep0 rowsep0" align="left">0.0011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.0092</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">0.00043</td><td class="colsep0 rowsep0" align="left">0.00072</td><td class="colsep0 rowsep0" align="left">0.0037</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">0.96/0.94</td><td class="colsep0 rowsep0" align="left">>10/1.9</td><td class="colsep0 rowsep0" align="left">0.22/0.08</td><td class="colsep0 rowsep0" align="left">3.5/0.1</td><td class="colsep0 rowsep0" align="left">3.3/0.13</td><td class="colsep0 rowsep0" align="left">>30/0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">760</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left"><20</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t2fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (rat heps)<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><3 (<1)</td><td class="colsep0 rowsep0" align="left">9.7 (41)</td><td class="colsep0 rowsep0" align="left">55 (7.8)</td><td class="colsep0 rowsep0" align="left">36 (6.2)</td><td class="colsep0 rowsep0" align="left">73 (22)</td><td class="colsep0 rowsep0" align="left">99 (9)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn0"><div class="footnote" id="t2fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements. IC<sub>50</sub> data reported as <0.0003 μM refer to values below the tight-binding limit of the ERK2 biochemical assays.</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t2fn2"><sup>c</sup><p class="last">Solubility of the compound in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t2fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM.</p></div><div class="footnote" id="t2fn4"><sup>e</sup><p class="last">Human liver microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and rat hepatocyte (μL min<sup>–1</sup> (million cells)<sup>−1</sup>) metabolic intrinsic clearance.</p></div><div class="footnote" id="t2fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">Our next objective was to grow lead compound <b>6</b> into the glycine-rich loop to gain additional interactions to drive the ERK1/2 potency and further improve the kinase selectivity. From our structural overlays, exemplified in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, we believed that it might be possible to achieve this through substitution of the lactam NH, and a range of potential groups were subsequently assessed and prioritized by molecular modeling with the docking package Glide from Schrödinger (Maestro version 2016-3)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> utilizing in-house crystal structures prepared by the ligand and protein preparation protocols. <b>7</b> was synthesized to check whether substitution was tolerated with a methyl group: although we saw a 10-fold decrease in potency (0.013 μM for <b>7</b> compared with 0.0012 μM for <b>6</b>), the observation encouraged us to add larger groups that may fill the glycine-rich loop more effectively. <b>8</b> was then synthesized with a benzyl substituent, which appeared to be well-accommodated on the basis of molecular modeling studies. Gratifyingly, we observed significantly improved biochemical and cellular activity (0.08 μM for <b>8</b> vs 0.94 μM for <b>6</b> in the pRSK MOA assay) with further-improved kinase selectivity (6 vs 14 with >80% inhibition at 1 μM for the same pair of compounds), albeit with an increase in log <i>D</i> and subsequent decrease in aqueous solubility. Compound <b>8</b> was crystallized in ERK2, where the overall binding mode was largely as predicted; the glycine-rich loop required reorganization of Tyr-36 to fully accommodate the group (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), as commented previously. It was also notable that the angle of <b>8</b> in the ATP pocket was shifted compared with that of <b>4</b>. This movement of the core between the two inhibitors suggested that further work in the glycine-rich loop group region might affect the structure–activity relationship (SAR) on different parts of the scaffold, which we considered in subsequent evolution of the series.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>4</b> elucidated in the human ERK2 crystal structure (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU">5NGU</a>) overlaid with <b>8</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHF">5NHF</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As the lipophilicity of compounds such as <b>8</b> (log <i>D</i><sub>7.4</sub> = 3.2) appeared to compromise the physicochemical properties (aqueous solubility < 20 μM), a hydroxyl group was added to the benzyl linker using SAR gleaned from literature ERK1/2 inhibitors such as <b>2</b>, <b>3</b>, and examples such as <b>5</b> by Aronov et al.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This change broadly maintained the ERK activity and kinase selectivity but reduced log <i>D</i> and resulted in improved solubility (the aqueous solubility of <b>9</b> was 250 μM). In an effort to understand whether the more specific reported phenylglycine-rich loop SAR would transfer to our template, <b>10</b> and <b>11</b> were synthesized with the hydroxymethyl-substituted 3-chloro-4-fluorobenzyl group in both enantiomeric forms, among others. <b>10</b> was the most potent example synthesized, but we were concerned about the impact of the high lipophilicity (log <i>D</i><sub>7.4</sub> = 3.6) on the solubility and other properties such as metabolic clearance, which was high in human liver microsomes (HLM), with a value of 73 μL min<sup>–1</sup> mg<sup>–1</sup>. An additional concern was that although the intrinsic permeability of <b>9</b> appeared to be acceptable in a Caco-2 assay with efflux inhibitors (A to B <i>P</i><sub>app</sub> = 12 × 10<sup>–6</sup> cm/s), we measured an efflux ratio of 24 in our Caco-2 efflux assay, which may limit the oral bioavailability. It was suspected that the additional hydroxyl group, which had successfully reduced the log <i>D</i> of the molecules, might contribute significantly to this liability. The profile of these more potent compounds appeared to show that they were primarily inhibitors of catalysis (IOCs), i.e., ATP-competitive inhibitors of ERK1/2 catalytic activity, because of their greater activity against pRSK than pERK in the cellular assays.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Optimization of the Pyrimidine–Pyrrololactam Series</h3><div class="NLM_p">One focus of this early work was to identify substituents that could interact in the glycine-rich loop region of ERK1/2 but have lower lipophilicity to give a more balanced overall compound profile. In particular, such a change might enable a reduction of log <i>D</i> for the compounds within this scaffold without the need for the hydroxyl group, which may compromise the permeability and/or efflux. A diverse set of compounds was synthesized to vary this position, and <b>12</b> and <b>13</b> appeared to be most interesting (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), having a reasonable balance of ERK2 inhibition and lipophilicity, as quantified by the cellular lipophilicity ligand efficiency (cellular LLE). The cellular LLE was derived by subtracting the measured log <i>D</i> from the pIC<sub>50</sub> in the pRSK cellular assay. The cellular LLE for <b>8</b> (3.4) was used as a benchmark for this work, and it was therefore encouraging to see compounds with increased LLE come from this compound set. <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> shows the binding mode for <b>12</b>, with the CH<sub>2</sub>CH<sub>2</sub>OMe group directed into the space previously occupied by the benzyl moiety. Water molecules were observed in the glycine-rich loop pocket with this group bound (but not with the benzyl group), suggesting that the pocket was not filled as fully by this group. However, the kinase selectivity was not only maintained but on occasions improved with these alternative glycine-rich loop interacting groups.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (left) Binding mode of <b>12</b> elucidated in the human ERK2 crystal structure (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH">5NHH</a>) overlaid with <b>14</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHJ">5NHJ</a>). (right) Binding mode of <b>17</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHL">5NHL</a>) overlaid with <b>18</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHO">5NHO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exemplar Compounds from the Pyrimidine–Pyrrololactam Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0013.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>13</b></th><th class="colsep0 rowsep0" align="center"><b>14</b></th><th class="colsep0 rowsep0" align="center"><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>16</b></th><th class="colsep0 rowsep0" align="center"><b>17</b></th><th class="colsep0 rowsep0" align="center"><b>18</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left"><0.00113</td><td class="colsep0 rowsep0" align="left">0.00047</td><td class="colsep0 rowsep0" align="left">0.00539</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">0.0019</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.0048</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">0.0025</td><td class="colsep0 rowsep0" align="left"><0.00033</td><td class="colsep0 rowsep0" align="left">0.014</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">18/0.6</td><td class="colsep0 rowsep0" align="left">9.4/0.37</td><td class="colsep0 rowsep0" align="left">>30/1.6</td><td class="colsep0 rowsep0" align="left">1.1/29</td><td class="colsep0 rowsep0" align="left">1.2/11.7</td><td class="colsep0 rowsep0" align="left">8.1/0.2</td><td class="colsep0 rowsep0" align="left">0.03/0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cellular LLE (pRSK)</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t3fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">2.11</td><td class="colsep0 rowsep0" align="left">2.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>370</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">627</td><td class="colsep0 rowsep0" align="left">619</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>774</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t3fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (rat heps)<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">9.8 (3)</td><td class="colsep0 rowsep0" align="left">24 (2.8)</td><td class="colsep0 rowsep0" align="left">5.1 (7.3)</td><td class="colsep0 rowsep0" align="left"><3 (<1)</td><td class="colsep0 rowsep0" align="left">6.3 (2.2)</td><td class="colsep0 rowsep0" align="left">26 (8.9)</td><td class="colsep0 rowsep0" align="left"><4.6 (<1.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 efflux ratio</td><td class="colsep0 rowsep0" align="left">10.2</td><td class="colsep0 rowsep0" align="left">19.6</td><td class="colsep0 rowsep0" align="left">43.5</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">33.4</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">11.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn0"><div class="footnote" id="t3fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements.</p></div><div class="footnote" id="t3fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t3fn2"><sup>c</sup><p class="last">Solubility of the compound in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t3fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM.</p></div><div class="footnote" id="t3fn4"><sup>e</sup><p class="last">Human liver microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and rat hepatocyte (μL min<sup>–1</sup> (million cells)<sup>−1</sup>) metabolic intrinsic clearance.</p></div><div class="footnote" id="t3fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">These structural changes, which reduced log <i>D</i> as hoped, reduced the in vitro clearance, although these were still relatively high in HLM. Cross-species in vitro metabolite identification work in hepatocytes had previously led us to identify the THP group as a metabolic liability, consistent with recent reports in the literature by Blake et al.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and others.<a onclick="showRef(event, 'ref18 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref25">(18, 25)</a> On the basis of this observation, we synthesized <b>14</b> containing a pyrazole group, which appeared to mitigate some of these liabilities while demonstrating good ERK2 activity and maintaining excellent kinase selectivity. The binding mode of this compound reveals that the nitrogen of the pyrazole has the potential to interact with Lys-114, similarly to the THP group, but this interaction was not always observed in crystal structures in examples such as <b>14</b>, potentially because of the inherent flexibility of the residue. The HLM clearance was 5.1 μL min<sup>–1</sup> mg<sup>–1</sup> for <b>14</b>, which appeared to confirm a reduced metabolic liability of compounds containing this moiety. With the aim to further improve the potency, ligand-bound crystal structures were analyzed to identify areas around <b>12</b> and <b>14</b> where the ATP pocket could be filled more effectively. A methyl group was subsequently added, positioned adjacent to the glycine-rich loop substituent. Synthesized initially as a racemate, the compound was isolated and tentatively assigned chirality by vibrational circular dichroism spectroscopy (VCD) (Experimental S2 in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">Supporting Information</a>). <b>15</b> appeared to be more potent than <b>16</b> in the biochemical assays (<0.00033 vs 0.014 μM at high ATP). However, there was no clear separation in activity in the MOA cellular assay (1.2 vs 1.1 μM in pRSK), although these changes did improve the solubility and lead to compounds with low in vitro clearances. At this stage, we decided to continue to assess the activity of both enantiomers and assign the chirality on key compounds only where further studies were justified. A further change was made by adding a methyl group at the 5-position of the pyrimidine to fill the space toward the gatekeeper residue (Gln-105) more optimally. Both <b>17</b> and <b>18</b> showed potent biochemical and cellular activity (0.2 and 0.13 μM in pRSK, respectively), and although the kinase selectivity appeared to be slightly reduced, the compounds were significantly more potent, so the absolute margin to some of those kinase targets may well be maintained. The additional methyl directed toward the gatekeeper residue appeared to be accommodated with little impact on the binding mode of the scaffold (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Although we did not attempt to assign absolute chirality to this pair using VCD, this was revealed through X-ray crystallography. The binding mode of <b>17</b> and <b>18</b> showed that the glycine-rich loop group was maintained in a similar position, again with water observed in the pocket, the chiral methyl pointed “up” (<b>17</b>) or “down” (<b>18</b>), and the lactam ring puckered to enable the appropriate geometry, leaving the hinge interaction largely unchanged. An interesting observation within this set was that <b>18</b> had increased activity against pERK (0.03 μM), which was not observed with closely related examples. It was also apparent that different glycine-rich loop groups may have different preferences for the chirality of this adjacent methyl, so we routinely synthesized both.</div><div class="NLM_p last">Although these modifications successfully improved the potency and reduced the in vitro clearance, efflux was still a potential concern. The compounds in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> highlight this with efflux ratios between 10 and 44. Examples from this series were tested in in vivo pharmacokinetic (PK) studies, where low oral bioavailability was observed in rat and high in vivo clearance in rat and mouse. However, increased compound exposure could be observed at higher doses in rat, suggesting that saturation of efflux transporters might be possible. Furthermore, increased exposures could also be achieved in mouse via codosing with 1-aminobenzotriazole (ABT), an irreversible inhibitor of cytochrome P450s, to reduce the metabolic component of the high in vivo clearance. With these issues in mind, we decided to further optimize the PK properties to identify a compound with the potential to modulate the target in vivo at low doses without the need for codosing with ABT, as this would complicate and compromise further studies such as xenograft efficacy experiments, in particular with respect to potential combination studies with other inhibitors of the pathway.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Core Change of the Pyrimidine–Pyrrololactam Series</h3><div class="NLM_p">To improve the PK properties of our compounds, we aimed to either modify or replace the pyrrololactam group, as the hydrogen-bond donor of the pyrrole was a concern in terms of efflux and/or permeability. Methylation of the NH was well-tolerated with exemplar <b>19</b> (0.0014 μM vs 0.0012 μM for <b>6</b>), and that encouraged us to make additional examples with extended glycine-rich loop groups. Reassuringly, the Caco-2 efflux ratios of such compounds were significantly reduced (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Methylation of Pyrrololactam NH</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0014.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>19</b></th><th class="colsep0 rowsep0" align="center"><b>20</b></th><th class="colsep0 rowsep0" align="center"><b>21</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left">0.0012</td><td class="colsep0 rowsep0" align="left">0.0014</td><td class="colsep0 rowsep0" align="left"><0.00048</td><td class="colsep0 rowsep0" align="left">0.0027</td><td class="colsep0 rowsep0" align="left">0.023</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.0092</td><td class="colsep0 rowsep0" align="left">0.0079</td><td class="colsep0 rowsep0" align="left">0.0016</td><td class="colsep0 rowsep0" align="left">0.024</td><td class="colsep0 rowsep0" align="left">0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">0.96/0.94</td><td class="colsep0 rowsep0" align="left">0.57/0.34</td><td class="colsep0 rowsep0" align="left">9.3/0.069</td><td class="colsep0 rowsep0" align="left">24/1.4</td><td class="colsep0 rowsep0" align="left">>10/4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn5" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">760</td><td class="colsep0 rowsep0" align="left">410</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t4fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (rat heps)<a class="ref internalNav" href="#t4fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><3 (<1)</td><td class="colsep0 rowsep0" align="left"><3 (<1.6)</td><td class="colsep0 rowsep0" align="left">84 (39)</td><td class="colsep0 rowsep0" align="left">11 (6.6)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 efflux ratio</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">6.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn0"><div class="footnote" id="t4fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements.</p></div><div class="footnote" id="t4fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t4fn2"><sup>c</sup><p class="last">Solubility of the compound in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t4fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM.</p></div><div class="footnote" id="t4fn4"><sup>e</sup><p class="last">Human liver microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and rat hepatocyte (μL min<sup>–1</sup> (million cells)<sup>−1</sup>) metabolic intrinsic clearance.</p></div><div class="footnote" id="t4fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">Of particular note was the improved kinase selectivity of the compound without the extended glycine-rich loop group (<b>19</b>) compared with the pyrrololactam matched pair <b>6</b>. As previously observed, we saw increased potency with the addition of the benzyl group into the glycine-rich loop pocket (0.069 for <b>20</b> vs 0.34 μM for <b>19</b> in pRSK), whereas the CH<sub>2</sub>CH<sub>2</sub>OMe equivalent was significantly less potent on this core (1.4 μM vs pRSK). An additional challenge was revealed when an example was synthesized with the pyrazole solvent channel group, where decreases in biochemical potency (0.24 for <b>22</b> vs 0.024 μM for <b>21</b> at high ATP) and cellular potency (4.7 μM versus pRSK) were observed, which we subsequently rationalized by the “clash” of the added methyl with the pyrazole, making the binding mode less favorable. <b>22</b> was soaked in our ERK2 structural system, and the binding mode was compared with that of <b>14</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Although subtle, there is a shift of the inhibitor core that appears to be required to enable the compound to bind. In addition, it is possible that the bound conformation of <b>22</b> is a higher-energy conformation relative to the global minimum in solution, although no attempt was made to characterize this further because the SAR clearly indicated that this combination of substituents was not well-tolerated by the protein.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>22</b> elucidated in the human ERK2 crystal structure (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP">5NHP</a>) overlaid with compound <b>12</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH">5NHH</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The focus of this work then moved on to the identification of additional cores to access compounds with reduced efflux that would tolerate the pyrazole solvent channel group. A number of fused ring systems were assessed on the basis of a molecular modeling evaluation of whether the ring system could enable the appropriate binding mode geometry. These computational studies involved calculating the energetics of the bond rotation between the pyrimidine hinge group and the fused ring system by quantum mechanics (QM) to assess whether the binding mode was likely to be favored or at least accessible without a significant energetic penalty. Selected calculations are reported in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, which shows that for the pyrrololactam systems (<b>A</b> and <b>B</b>) the binding mode as drawn is at a minimum of the torsional energetic profile (0°), which was also the case for the newly identified pyrrolopyrazinone system (<b>C</b>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. QM torsion profile of an alternative pyrrolopyrazinone ring system (<b>C</b>) compared with those of pyrrololactam cores <b>A</b> and <b>B</b>. Gas-phase energies (in kcal/mol) were calculated in Jaguar (Maestro version 2016-3, Schrödinger) using a relaxed coordinate scan with an increment of 5° (d) using density functional theory with the B3LYP functional and the 6-31G** basis set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In parallel, the likely physicochemical properties and chemical feasibility of such alternative cores were assessed. Our first example containing core <b>C</b> (<b>23</b>) showed respectable potency and kinase selectivity compared with the equivalent compounds with <b>A</b> and <b>B</b> cores. Since we carried out this work, this ring system has been independently reported in ERK1/2 inhibitors by Bagdanoff et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> from focused screening. Additional examples were then synthesized, informed by mapping of the previously identified SAR from the pyrrololactam cores onto a pyrrolopyrazinone scaffold, including both solvent channel and glycine-rich loop groups along with the “flanking methyl” groups. This approach was supported by the crystal structure of <b>23</b>, which showed an almost identical binding mode as the previously described pyrrololactam <b>14</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">Figure S2</a>). These compounds not only showed good biochemical and cellular potency, but also the lipophilicity was lower than previous examples (log <i>D</i> ∼ 2) which gratifyingly resulted in lower in vitro clearances. In particular, the pyridine glycine-rich loop compounds were attractive in terms of potency and properties such as solubility (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Two key compounds, <b>24</b> and <b>25</b> (absolute stereochemistry unassigned), helped build confidence that the previous SAR in the glycine -rich loop region reported in this article could be mapped onto this alternative core (0.33 μM pRSK cell activity for <b>24</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pyrrolopyrazinone Series Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0015.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>23</b></th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>25</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left">0.0028</td><td class="colsep0 rowsep0" align="left"><0.00039</td><td class="colsep0 rowsep0" align="left">0.0029</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.037</td><td class="colsep0 rowsep0" align="left">0.00035</td><td class="colsep0 rowsep0" align="left">0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">25/1.1</td><td class="colsep0 rowsep0" align="left">22/0.33</td><td class="colsep0 rowsep0" align="left">>30/0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t5fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t5fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">770</td><td class="colsep0 rowsep0" align="left">560</td><td class="colsep0 rowsep0" align="left">710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t5fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (rat heps)<a class="ref internalNav" href="#t5fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><3 (<1)</td><td class="colsep0 rowsep0" align="left">8.9 (2.7)</td><td class="colsep0 rowsep0" align="left"><3 (6.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 efflux ratio</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">4.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn0"><div class="footnote" id="t5fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements. IC<sub>50</sub> data reported as <0.0003 μM refer to values below the tight-binding limit of the ERK2 biochemical assays.</p></div><div class="footnote" id="t5fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t5fn2"><sup>c</sup><p class="last">Solubility of the compound in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t5fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM.kinase selectivity <i>N</i><sub>>80%</sub></p></div><div class="footnote" id="t5fn4"><sup>e</sup><p class="last">Human liver microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and rat hepatocyte (μL min<sup>–1</sup> (million cells)<sup>−1</sup>) metabolic intrinsic clearance.</p></div><div class="footnote" id="t5fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">The change in core also enabled the identification of compounds with lower efflux ratios along with high intrinsic permeability (<b>25</b>, Caco-2 A to B <i>P</i><sub>app</sub> = 50 × 10<sup>–6</sup> cm/s). A further iteration of compounds was then synthesized to include the 5-substituent pyrimidine SAR previously identified, which led to a number of key examples for further assessment and the most interesting examples from this work to date (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Compounds <b>26</b>–<b>29</b>, <b>35</b>, and <b>36</b> were highly potent and in a log <i>D</i> range where we expected good solubility. With potencies generally approaching (or at) the tight-binding limit of the biochemical assays, the cellular activity of these compounds became the key driver in terms of compound assessment. The cellular pRSK assay identified <b>35</b> as particularly potent, and it benefitted from good in vitro properties, including excellent aqueous solubility (>480 μM) and low in vitro clearance (<1 μL min<sup>–1</sup> (million cells)<sup>−1</sup> in human hepatocytes) along with good permeability (52 × 10<sup>–6</sup> cm/s) and a moderate Caco-2 efflux ratio (9.6). The cellular MOA A375 pERK/pRSK potency of <b>35</b> (0.012/0.062 μM) was lower than of <b>1</b> (0.004/0.02 μM) but compared favorably to those of <b>2</b> and <b>3</b> in the same assays (4.1/0.14 μM and 0.031/0.086 μM, respectively). The kinase selectivity was also favorable, and consistent with previous examples, the profile of <b>35</b> across a 288 kinase panel is shown in Table S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">Supporting Information</a>. As we expected these compounds to have highly desirable profiles, both enantiomers were synthesized to enable full characterization and profiling. There was also on occasion an impact of the chirality on the apparent MOA that we were unable to explain, with <b>29</b> and <b>35</b> appearing to inhibit pERK to a greater extent than compounds previously synthesized within this template, consistent with a dual inhibition of catalysis (IOC) and prevention of activation (POA) profile. A profile that prevents the activation of ERK1/2 may arise from an binding of an inhibitor to the protein in a conformation that precludes the binding of MEK. These data suggest that varying the interactions between the ligand and protein in the glycine-rich loop region might be able to influence the mechanistic profile of ERK1/2 small-molecule inhibitors, and additional studies to understand this would be valuable.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary Table of the Best Combinations on the Pyrrolopyrazinone Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0016.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>27</b></th><th class="colsep0 rowsep0" align="center"><b>28</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>35</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn0" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>K</i><sub>M</sub> ATP</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP</td><td class="colsep0 rowsep0" align="left">0.0003</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">0.0009</td><td class="colsep0 rowsep0" align="left"><0.0003</td><td class="colsep0 rowsep0" align="left">0.0005</td><td class="colsep0 rowsep0" align="left">0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK</td><td class="colsep0 rowsep0" align="left">>1/0.11</td><td class="colsep0 rowsep0" align="left">>30/0.31</td><td class="colsep0 rowsep0" align="left">>30/0.14</td><td class="colsep0 rowsep0" align="left">0.38/0.31</td><td class="colsep0 rowsep0" align="left">0.012/0.062</td><td class="colsep0 rowsep0" align="left">22/0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t6fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t6fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">690</td><td class="colsep0 rowsep0" align="left">350</td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left">>480</td><td class="colsep0 rowsep0" align="left">620</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity <i>N</i><sub>>80%</sub><a class="ref internalNav" href="#t6fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">9*</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn5" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (human/rat heps)<a class="ref internalNav" href="#t6fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><3.5 (1.8)</td><td class="colsep0 rowsep0" align="left"><3 (16)</td><td class="colsep0 rowsep0" align="left"><3 (8.9)</td><td class="colsep0 rowsep0" align="left"><3 (1.5)</td><td class="colsep0 rowsep0" align="left"><4.8 (<1/17)</td><td class="colsep0 rowsep0" align="left">5.7 (5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 A to B <i>P</i><sub>app</sub> + inhibitors (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 efflux ratio</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">11.6</td><td class="colsep0 rowsep0" align="left">11.8</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">7.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn0"><div class="footnote" id="t6fn0"><sup>a</sup><p class="last">All of the IC<sub>50</sub> data are means of at least <i>n</i> = 3 independent measurements. IC<sub>50</sub> data reported as <0.0003 μM refer to values below the tight-binding limit of the ERK2 biochemical assays.</p></div><div class="footnote" id="t6fn1"><sup>b</sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t6fn2"><sup>c</sup><p class="last">Solubility of the compound in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C.</p></div><div class="footnote" id="t6fn3"><sup>d</sup><p class="last">Number of kinases that were >80% inhibited in a panel of 128 kinases. Kinase selectivity data were measured at a compound concentration of 1 μM. The value marked with * is from a test on a broader set of 288 kinases.</p></div><div class="footnote" id="t6fn4"><sup>e</sup><p class="last">Human liver microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and human/rat hepatocyte (μL min<sup>–1</sup> (million cells)<sup>−1</sup>) metabolic intrinsic clearance.</p></div><div class="footnote" id="t6fn5"><sup>f</sup><p class="last">ND = not determined.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p">The synthesis of <b>35</b> was performed in a six-step sequence as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Starting from 1-BOC-2-(methoxycarbonyl)pyrrole-4-boronic acid pinacol ester, a Suzuki–Miyaura cross-coupling reaction with 2,4-dichloro-5-methylpyrimidine followed by deprotection afforded pyrrole <b>31</b>. Reaction of the pyrrole with a BOC-sulfamidate followed by subsequent deprotection resulted in spontaneous lactam formation under basic conditions to deliver dihydropyrrolopyrazinone <b>33</b>. Deprotonation of the lactam followed by alkylation with 2-(chloromethyl)-6-methylpyridine yielded tertiary lactam <b>34</b>. Finally, the 1-methyl-1<i>H</i>-pyrazol-5-amino moiety was introduced by Buchwald–Hartwig cross-coupling using BrettPhos third-generation precatalyst to afford <b>35</b> in good yield. Full experimental details on the synthesis and characterization of <b>35</b> can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, and details on all final compounds reported can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">Experimental S1</a>.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, water, 80 °C, 64%; (ii) HCl, 1,4-dioxane, MeOH, 99%; (iii) K<sub>2</sub>CO<sub>3</sub>, 18-crown-6, 1,4-dioxane, 100 °C, 93%; (iv) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 22 °C, then NH<sub>3</sub>, MeOH, 22 °C, 95%; (v) NaH, DMF, 20 °C, 83%; (vi) third-generation BrettPhos precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, <i>t-</i>BuOH, 80 °C, 77%.</p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacokinetic Studies on Lead Compound <b>35</b></h3><div class="NLM_p">On the basis of its overall properties, <b>35</b> was selected for further assessment of its potential in in vivo target modulation studies. <b>35</b> subsequently showed excellent in vivo PK properties in mouse, rat, and dog studies, confirming its suitability as an in vivo ERK1/2 inhibitor (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Oral bioavailability in rat was measured at 31%, with 87% bioavailability in dog. A 100 mg/kg oral dose in mouse gave free cover over the cellular pRSK IC<sub>50</sub> for around 18 h (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). To understand the potential of this compound as an advanced candidate, we calculated a predicted dose to human of 91–251 mg using scaled human hepatocyte data, correcting volume estimates for protein binding differences from preclinical species and requiring free cover for 12 h over pRSK IC<sub>50</sub>, as summarized in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> with predicted human PK parameters.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The extent and duration of cover were chosen on the basis of the coverage required to observe tumor regression in the Calu-6 in vivo model.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (left) Free plasma concentrations in nude mice following 100 mg/kg daily oral dose of <b>35</b> in relation to cover over pRSK IC<sub>50</sub>. (right) PK properties and early dose to human predictions for <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacodynamic and Efficacy Studies on Lead Compound <b>35</b></h3><div class="NLM_p">In vivo pharmacodynamic (PD) evaluation and antitumor xenograft studies were subsequently carried out in the Calu-6 nonsmall cell lung cancer (NSCLC) model. It has been widely reported that the KRAS mutant cell lines can be both sensitive and insensitive in vitro to inhibition of the MAPK pathway.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The NSCLC Calu-6 cell line possesses a mutation in the KRAS gene (Q61H) and has been demonstrated to be sensitive in vitro to MEK inhibition, and Calu-6 xenografts were strongly growth-inhibited by the allosteric MEK inhibitor selumetinib.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the basis of this known response to in vitro and in vivo MAPK pathway inhibition, the Calu-6 cell line was selected as a relevant model for this study.</div><div class="NLM_p">Gratifyingly, an increase in the free plasma concentration of <b>35</b> was observed in animals tested with increasing doses of 10, 30, and 100 mg/kg, and this was coupled with an overall decrease in the level of pRSK (phospho-p90RSK), a downstream target of ERK1/2 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). A dose–response relationship was observed when mice were tested chronically with <b>35</b> for 17 days (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). Tumor regression was observed at compound doses of 15 and 50 mg/kg Q.D., albeit transiently at the lower dose of 15 mg/kg Q.D.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PD evaluation of <b>35</b> in the Calu-6 in vivo model of NSCLC. The bar charts show average percent pRSK expression normalized to vehicle controls over time. The line charts show average concentration of free drug (PK) over time. Error bars show ±SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor efficacy of <b>35</b> in the Calu-6 NSCLC model. The plots show average tumor volume of Calu-6 over time upon treatment with an oral formulation of <b>35</b> at 5, 15, or 50 mg/kg Q.D. Average volumes are geomeans, and error bars show ±SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74322" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74322" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described an approach for the identification of potent and selective reversible ERK1/2 inhibitors utilizing in-house kinase selectivity panel data as a start point, followed by the rapid evolution using knowledge of the compound binding mode. A number of these compounds have excellent biochemical and cellular ERK potencies and are highly selective for ERK1/2 in kinase selectivity panels. An exemplar compound from this work (<b>35</b>) was dosed in a mouse antitumor study and demonstrated robust tumor regression at a 50 mg/kg daily dose. In addition, this compound had a relatively low predicted human dose (91–251 mg), showing that further evaluation of compounds from this series is justified.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Analytical Information</h3><div class="NLM_p last">NMR spectra were recorded on a Bruker 300, 400, or 500 MHz instrument at room temperature, unless otherwise stated. All of the <sup>1</sup>H NMR spectra were measured in parts per million (ppm) relative to the signal for residual dimethyl sulfoxide (DMSO) in deuterated DMSO (2.50 ppm) or the signal for tetramethylsilane added to the deuterated chloroform (0 ppm). The <sup>1</sup>H NMR data are reported as chemical shift (multiplicity, coupling constant(s), integration). Multiplicities are indicated as s = singlet, d = doublet, t = triplet, q = quartet, h = heptet, m = multiplet, and br = broad. LC–MS analyses were performed on a Waters 2795 separations module using a Gemini NX-C18 column with a Waters Micromass detector. All final compounds were found to be of 95% purity or greater by LC–MS.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis and Characterization of Compound <b>35</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 1-<i>tert</i>-Butyl 2-Methyl 4-(2-Chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrrole-1,2-dicarboxylate (<b>30</b>)</h4><div class="NLM_p last">Tetrakis(triphenylphosphine)palladium(0) (0.98 g, 0.85 mmol) was added to a degassed solution of 2,4-dichloro-5-methylpyrimidine (4.6 g, 28 mmol), 1-<i>tert</i>-butyl 2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrole-1,2-dicarboxylate (10 g, 28 mmol), and potassium phosphate (18 g, 85 mmol) in dioxane (120 mL) and water (30 mL) at 22 °C under nitrogen. The resulting solution was stirred at 80 °C for 4 h. The reaction mixture was concentrated and diluted with EtOAc (150 mL) and brine (100 mL). The layers were partitioned, and then the aqueous layer was extracted with further EtOAc (2 × 150 mL). The combined organics were evaporated to afford the crude product. The crude product was purified by flash silica chromatography, with 5–50% EtOAc in heptane as the elution solvent. Pure fractions were evaporated to dryness to afford <b>30</b> (6.4 g, 64%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.56 (s, 9H), 2.41–2.47 (m, 3H), 3.83 (s, 3H), 7.39 (d, <i>J</i> = 1.9 Hz, 1H), 8.01 (d, <i>J</i> = 1.9 Hz, 1H), 8.61 (d, <i>J</i> = 0.7 Hz, 1H); ES<sup>+</sup> [M – BOC + H]<sup>+</sup><i>m</i>/<i>z</i> 252.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Methyl 4-(2-Chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrrole-2-carboxylate (<b>31</b>)</h4><div class="NLM_p last">Hydrogen chloride (4.0 M in dioxane, 45 mL, 180 mmol) was added to <b>30</b> (6.4 g, 18 mmol) in methanol (40 mL) at 22 °C. The resulting mixture was stirred at 22 °C for 18 h. The white solid was collected by filtration and washed with diethyl ether. The solid was added to water (150 mL) and EtOH (20 mL), and the suspension was stirred for 30 min, after which 2 M aqueous sodium carbonate (40 mL) was added. The product was extracted with DCM (3 × 200 mL). The combined organics were concentrated to yield <b>31</b> (4.6 g, 100%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.38–2.45 (m, 3H), 3.81 (s, 3H), 7.39 (d, <i>J</i> = 1.7 Hz, 1H), 7.72 (d, <i>J</i> = 1.7 Hz, 1H), 8.50 (s, 1H), 12.64 (s, 1H); ES<sup>+</sup> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 252.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>R</i>)-Methyl 1-(2-((<i>tert-</i>Butoxycarbonyl)amino)propyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrrole-2-carboxylate (<b>32</b>)</h4><div class="NLM_p last">Potassium carbonate (40 g, 287 mmol) was added to (<i>R</i>)-<i>tert</i>-butyl 4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (9.8 g, 42 mmol), <b>31</b> (8 g, 32 mmol), and 18-crown-6 (2.1 g, 8 mmol) in 1,4-dioxane (100 mL) at 22 °C under nitrogen. The resulting mixture was stirred at 100 °C for 16 h. The mixture was diluted with ethyl acetate (600 mL), washed with water (3 × 300 mL) and saturated brine (200 mL), dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by flash silica chromatography using an elution gradient of 0 to 60% EtOAc in heptane. Pure fractions were evaporated to dryness to afford <b>32</b> (12 g, 93%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.08 (d, <i>J</i> = 6.6 Hz, 3H), 1.16 (s, 9H), 2.42 (s, 3H), 3.80 (s, 3H), 3.83–4.02 (m, 2H), 4.60 (dd, <i>J</i> = 3.2, 12.9 Hz, 1H), 6.77 (d, <i>J</i> = 9.0 Hz, 1H), 7.43 (s, 1H), 7.81 (s, 1H), 8.51 (s, 1H); ES<sup>+</sup> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 409.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>R</i>)-7-(2-Chloro-5-methylpyrimidin-4-yl)-3-methyl-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>33</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (30 mL) was added to <b>32</b> (7.6 g, 19 mmol) in DCM (53 mL) at 22 °C. The resulting mixture was stirred at 22 °C for 2 h. The resulting solution was concentrated and then purified by ion exchange chromatography. The desired product was eluted from the column using 1 M ammonia/methanol solution and evaporated to dryness to afford (<i>R</i>)-methyl 1-(2-aminopropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrrole-2-carboxylate as an off-white solid. This material was dissolved in DCM (50 mL), and then 7 M ammonia/methanol solution (100 mL) was added. The solution was stirred at ambient temperature for a further 18 h, after which the reaction mixture was concentrated and the residue triturated with ether to yield <b>33</b> (4.90 g, 95%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.20 (d, <i>J</i> = 5.9 Hz, 3H), 2.42 (s, 3H), 3.83–3.93 (m, 2H), 4.25–4.35 (m, 1H), 7.23 (d, <i>J</i> = 1.7 Hz, 1H), 7.81 (d, <i>J</i> = 1.7 Hz, 1H), 7.92 (s, 1H), 8.49 (s, 1H); ES<sup>+</sup> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 277.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-7-(2-Chloro-5-methylpyrimidin-4-yl)-3-methyl-2-((6-methylpyridin-2-yl)methyl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>34</b>)</h4><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil) (1.1 g, 27 mmol) was added to <b>33</b> (7 g, 25 mmol) in DMF (150 mL) at 22 °C under nitrogen. The resulting suspension was stirred at room temperature for 30 min. 2-(Chloromethyl)-6-methylpyridine (3.7 g, 26 mmol) in DMF (10 mL) was added, and the resulting solution was stirred at 22 °C for 18 h. The reaction mixture was diluted with ethyl acetate (400 mL) and quenched with saturated NH<sub>4</sub>Cl (400 mL). The organic layer was washed with brine (400 mL) and water (400 mL) and then concentrated. A small amount of solid was observed in the final aqueous layer, which was isolated by filtration (confirmed to be pure product) and added to the crude product. The crude product was stirred in diethyl ether (150 mL) for 1 h, collected by filtration, and dried under vacuum to yield <b>34</b> (7.9 g, 83%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.15 (d, <i>J</i> = 6.6 Hz, 3H), 2.43 (s, 3H), 2.46 (s, 3H), 3.98 (ddd, <i>J</i> = 2.4, 4.2, 6.6 Hz, 1H), 4.23 (dd, <i>J</i> = 2.3, 13.1 Hz, 1H), 4.30 (d, <i>J</i> = 16.0 Hz, 1H), 4.38 (dd, <i>J</i> = 4.3, 13.1 Hz, 1H), 5.13 (d, <i>J</i> = 16.0 Hz, 1H), 7.15 (t, <i>J</i> = 6.9 Hz, 2H), 7.28 (d, <i>J</i> = 1.7 Hz, 1H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.85 (d, <i>J</i> = 1.7 Hz, 1H), 8.50 (s, 1H); ES<sup>+</sup> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 382.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-3-Methyl-7-(5-methyl-2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)-2-((6-methylpyridin-2-yl)methyl)-3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one (<b>35</b>)</h4><div class="NLM_p last"><b>34</b> (130 mg, 0.35 mmol), 1-methyl-1<i>H</i>-pyrazol-5-amine (37 mg, 0.38 mmol), and cesium carbonate (250 mg, 0.77 mmol) were suspended in <i>tert</i>-butanol (3 mL) and degassed for 5 min, and then BrettPhos third-generation precatalyst (16 mg, 0.02 mmol) was added. The reaction mixture was heated to 83 °C for 2 h. The resulting mixture was diluted with EtOAc (30 mL) and washed with brine (30 mL). The aqueous layer was extracted with DCM (2 × 30 mL), and then the combined organics were evaporated to afford the crude product. The crude product was purified by flash silica chromatography using an elution gradient of 0.5 to 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford <b>35</b> (120 mg, 77%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.15 (d, <i>J</i> = 6.6 Hz, 3H), 2.32 (s, 3H), 2.46 (s, 3H), 3.68 (s, 3H), 3.96 (dt, <i>J</i> = 3.4, 6.7 Hz, 1H), 4.20 (dd, <i>J</i> = 2.3, 13.0 Hz, 1H), 4.29 (d, <i>J</i> = 15.9 Hz, 1H), 4.36 (dd, <i>J</i> = 4.2, 13.0 Hz, 1H), 5.13 (d, <i>J</i> = 16.0 Hz, 1H), 6.26 (d, <i>J</i> = 1.8 Hz, 1H), 7.15 (dd, <i>J</i> = 4.6, 7.6 Hz, 2H), 7.25 (d, <i>J</i> = 1.7 Hz, 1H), 7.32 (d, <i>J</i> = 1.9 Hz, 1H), 7.61–7.68 (m, 2H), 8.23 (s, 1H), 9.06 (s, 1H); <sup>13</sup>C NMR (176 MHz, DMSO-<i>d</i><sub>6</sub>) δ 16.8, 16.9, 23.9, 35.3, 48.7, 48.8, 51.5, 97.8, 112.3, 116.6, 118.2, 121.5, 122.8, 124.2, 126.0, 137.0, 137.1, 138.7, 156.9, 157.3, 157.5, 158.5, 158.6, 159.7; Purity 99.7% by LC–MS, ES<sup>+</sup> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 443; HRMS (ES<sup>+</sup>) for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O (MH<sup>+</sup>) calculated 443.23023, found 443.23032.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Animal Studies</h3><div class="NLM_p last">All animal work was compliant with the UK Animals (Scientific Procedures) Act, which is consistent with EU Directive 2010/63/EU. Female athymic Nude-Foxn1<sup>nu</sup> mice (Harlan) were housed under specific pathogen-free conditions in individually ventilated cages. Calu-6 nonsmall cell-lung cancer cells were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum and 1% <span class="smallcaps smallerCapital">l</span>-glutamine (Sigma-Aldrich) under standard cell culture conditions. Cells were harvested, and mice were injected subcutaneously with 100 μL of a 1 × 10<sup>6</sup> cell suspension of Calu-6 cells in 1:1 (v/v) mice of Matrigel (Becton Dickinson). Tumor growth was monitored by caliper measurement, and the volume was calculated using the equation (3.142 × Max(Length:Width) × Min(Length:Width) × Min(Length:Width))/6000. Mice were enrolled in the study when they reached a size of 0.4 cm<sup>3</sup> for the PK/PD experiment and 0.2 cm<sup>3</sup> for the efficacy experiment; both studies were appropriately statistically powered.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> PD and Efficacy Evaluation</h3><div class="NLM_p last">To evaluate the acute PD effect of <b>35</b>, animals were dosed orally with the compound formulated in 10:90 DMSO/40% Kleptose solution and euthanized at a range of time points after dosing, after which terminal blood samples were taken for mass spectrometry quantification of compound levels and tumors were excised and snap-frozen for Western blot analysis. Western blot was carried out as described previously<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> with antibodies against phospho-p90RSK (Abcam). For the efficacy study, mice were dosed for 17 days, and tumor volumes were measured twice weekly. The geomean (average of log<sub>10</sub>(volume)) of each group was calculated and plotted using GraphPad Prism 6 for Windows (Graph Pad Software Inc.).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Biochemical and Cellular Assays</h3><div class="NLM_p last">A full description of compound handling and experimental methods for all of the biochemical and cellular assays used in this work can be found in our previous publication.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> ERK2 Protein Crystal Structures</h3><div class="NLM_p">Protein crystals were generated using the hanging drop technique by mixing equal volumes of protein solution (approximately 10 mg/mL human ERK2 in 20 mM HEPES pH 7.8, 200 mM NaCl, 0.5 mM TCEP) and crystallization buffer (30% PegMME2K, 100 mM HEPES pH 7.6, 200 mM ammonium sulfate). Data collections were carried out at the Diamond Light Source and ESRF synchrotron beamlines at cryogenic temperatures using ethylene glycol as a cryoprotectant. The pipedream and autoBUSTER software packages were used to solve and refine the structures, and the program Coot was used for manual building of the models. Data collection and refinement statistics are listed in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. ERK2 Protein Crystal Structure Data Collection and Refinement Statistics</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>14</b></th><th class="colsep0 rowsep0" align="center"><b>17</b></th><th class="colsep0 rowsep0" align="center"><b>18</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th><th class="colsep0 rowsep0" align="center"><b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB code</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU">5NGU</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHF">5NHF</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH">5NHH</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHJ">5NHJ</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHL">5NHL</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHO">5NHO</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP">5NHP</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHV">5NHV</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="center">Data Collection Statistics<a class="ref internalNav" href="#t6afn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i> [Å]</td><td class="colsep0 rowsep0" align="left">49.01</td><td class="colsep0 rowsep0" align="left">49.02</td><td class="colsep0 rowsep0" align="left">48.58</td><td class="colsep0 rowsep0" align="left">49.03</td><td class="colsep0 rowsep0" align="left">48.91</td><td class="colsep0 rowsep0" align="left">48.91</td><td class="colsep0 rowsep0" align="left">48.79</td><td class="colsep0 rowsep0" align="left">48.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>b</i> [Å]</td><td class="colsep0 rowsep0" align="left">71.14</td><td class="colsep0 rowsep0" align="left">70.05</td><td class="colsep0 rowsep0" align="left">70.49</td><td class="colsep0 rowsep0" align="left">71.16</td><td class="colsep0 rowsep0" align="left">71.34</td><td class="colsep0 rowsep0" align="left">71.80</td><td class="colsep0 rowsep0" align="left">71.11</td><td class="colsep0 rowsep0" align="left">70.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>c</i> [Å]</td><td class="colsep0 rowsep0" align="left">60.64</td><td class="colsep0 rowsep0" align="left">60.36</td><td class="colsep0 rowsep0" align="left">61.46</td><td class="colsep0 rowsep0" align="left">61.4</td><td class="colsep0 rowsep0" align="left">61.16</td><td class="colsep0 rowsep0" align="left">61.25</td><td class="colsep0 rowsep0" align="left">61.03</td><td class="colsep0 rowsep0" align="left">60.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β [deg]</td><td class="colsep0 rowsep0" align="left">110.06</td><td class="colsep0 rowsep0" align="left">109.30</td><td class="colsep0 rowsep0" align="left">111.81</td><td class="colsep0 rowsep0" align="left">112.01</td><td class="colsep0 rowsep0" align="left">111.05</td><td class="colsep0 rowsep0" align="left">111.43</td><td class="colsep0 rowsep0" align="left">111.03</td><td class="colsep0 rowsep0" align="left">110.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution [Å]</td><td class="colsep0 rowsep0" align="left">2.75</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">1.94</td><td class="colsep0 rowsep0" align="left">2.12</td><td class="colsep0 rowsep0" align="left">2.07</td><td class="colsep0 rowsep0" align="left">2.24</td><td class="colsep0 rowsep0" align="left">1.99</td><td class="colsep0 rowsep0" align="left">2.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unique reflections</td><td class="colsep0 rowsep0" align="left">4692 (743)</td><td class="colsep0 rowsep0" align="left">20963 (1989)</td><td class="colsep0 rowsep0" align="left">28525 (2112)</td><td class="colsep0 rowsep0" align="left">21741 (1920)</td><td class="colsep0 rowsep0" align="left">23548 (1744)</td><td class="colsep0 rowsep0" align="left">18618 (1351)</td><td class="colsep0 rowsep0" align="left">26082 (3311)</td><td class="colsep0 rowsep0" align="left">25618 (8914)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiplicity</td><td class="colsep0 rowsep0" align="left">3.2 (3.3)</td><td class="colsep0 rowsep0" align="left">1.5 (1.4)</td><td class="colsep0 rowsep0" align="left">3.2 (3.2)</td><td class="colsep0 rowsep0" align="left">3.3 (3.2)</td><td class="colsep0 rowsep0" align="left">3.1 (3.2)</td><td class="colsep0 rowsep0" align="left">3.2 (3.2)</td><td class="colsep0 rowsep0" align="left">3.3 (3.3)</td><td class="colsep0 rowsep0" align="left">3.4 (3.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness [%]</td><td class="colsep0 rowsep0" align="left">97.3 (97.9)</td><td class="colsep0 rowsep0" align="left">98.2 (96.4)</td><td class="colsep0 rowsep0" align="left">99.2 (99.6)</td><td class="colsep0 rowsep0" align="left">97.7 (87.8)</td><td class="colsep0 rowsep0" align="left">98.1 (98.9)</td><td class="colsep0 rowsep0" align="left">97.7 (97.7)</td><td class="colsep0 rowsep0" align="left">97.8 (96.9)</td><td class="colsep0 rowsep0" align="left">97.4 (97.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>sym</sub> [%]</td><td class="colsep0 rowsep0" align="left">0.141 (0.537)</td><td class="colsep0 rowsep0" align="left">0.081 (0.792)</td><td class="colsep0 rowsep0" align="left">0.05 (0.520)</td><td class="colsep0 rowsep0" align="left">0.077 (0.723)</td><td class="colsep0 rowsep0" align="left">0.075 (0.340)</td><td class="colsep0 rowsep0" align="left">0.058 (0.612)</td><td class="colsep0 rowsep0" align="left">0.068 (0.357)</td><td class="colsep0 rowsep0" align="left">0.072 (0.368)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean(<i>I</i>)/SD</td><td class="colsep0 rowsep0" align="left">6.6 (1.9)</td><td class="colsep0 rowsep0" align="left">9.5 (1.6)</td><td class="colsep0 rowsep0" align="left">14.8 (2.1)</td><td class="colsep0 rowsep0" align="left">10.6 (1.5)</td><td class="colsep0 rowsep0" align="left">8.3 (2.7)</td><td class="colsep0 rowsep0" align="left">10.9 (1.7)</td><td class="colsep0 rowsep0" align="left">11.5 (3.7)</td><td class="colsep0 rowsep0" align="left">11.2 (3.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="center">Refinement Statistics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of reflections (working/test)</td><td class="colsep0 rowsep0" align="left">10077/485</td><td class="colsep0 rowsep0" align="left">20940/1312</td><td class="colsep0 rowsep0" align="left">28506/1775</td><td class="colsep0 rowsep0" align="left">21753/1108</td><td class="colsep0 rowsep0" align="left">23532/1475</td><td class="colsep0 rowsep0" align="left">18601/1166</td><td class="colsep0 rowsep0" align="left">26063/1651</td><td class="colsep0 rowsep0" align="left">25601/1596</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>/<i>R</i><sub>free</sub> [%]</td><td class="colsep0 rowsep0" align="left">26.46/26.41</td><td class="colsep0 rowsep0" align="left">24.8/25.9</td><td class="colsep0 rowsep0" align="left">18.3/22.0</td><td class="colsep0 rowsep0" align="left">20.1/20.7</td><td class="colsep0 rowsep0" align="left">21.1/23.7</td><td class="colsep0 rowsep0" align="left">20.1/23.1</td><td class="colsep0 rowsep0" align="left">19.9/22.1</td><td class="colsep0 rowsep0" align="left">18.6/22.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">deviation from ideal geometry</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond lengths [Å]</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond angles [deg]</td><td class="colsep0 rowsep0" align="left">1.100</td><td class="colsep0 rowsep0" align="left">1.22</td><td class="colsep0 rowsep0" align="left">1.00</td><td class="colsep0 rowsep0" align="left">1.00</td><td class="colsep0 rowsep0" align="left">0.97</td><td class="colsep0 rowsep0" align="left">1.08</td><td class="colsep0 rowsep0" align="left">0.93</td><td class="colsep0 rowsep0" align="left">1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">Ramachandran plot [%]</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">preferred region</td><td class="colsep0 rowsep0" align="left">97.0</td><td class="colsep0 rowsep0" align="left">97.0</td><td class="colsep0 rowsep0" align="left">95.3</td><td class="colsep0 rowsep0" align="left">96.8</td><td class="colsep0 rowsep0" align="left">96.2</td><td class="colsep0 rowsep0" align="left">95.6</td><td class="colsep0 rowsep0" align="left">96.1</td><td class="colsep0 rowsep0" align="left">97.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">generously allowed region</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">disallowed region</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6afn1"><div class="footnote" id="t6afn1"><sup>a</sup><p class="last">Data in parentheses refer to the highest-resolution shell.</p></div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00267">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00267" class="ext-link">10.1021/acs.jmedchem.7b00267</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional data analyses, experimental information, and compound characterization (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf">jm7b00267_si_001.pdf (972.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_002.csv">jm7b00267_si_002.csv (1.72 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00267" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Ward</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2310-9477" title="Orcid link">http://orcid.org/0000-0002-2310-9477</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c1b3a8a2a9a0b3a5efa0efb6a0b3a581a0b2b5b3a0bba4afa4a2a0efa2aeac"><span class="__cf_email__" data-cfemail="f88a919b90998a9cd699d68f998a9cb8998b8c8a99829d969d9b99d69b9795">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Bethel</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Calum Cook</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma Davies</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judit E. Debreczeni</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Fairley</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lyman Feron</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vikki Flemington</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Graham</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Greenwood</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Griffin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lyndsey Hanson</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Hopcroft</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tina D. Howard</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian Hudson</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael James</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clifford D. Jones</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher R. Jones</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Lamont</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Lewis</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Lindsay</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Roberts</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iain Simpson</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve St-Gallay</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Swallow</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Tang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6
Taihe Road BDA, Beijing, 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Tonge</span> - <span class="hlFld-Affiliation affiliation">IMED
Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building,
c/o Darwin Building, 310 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenhua Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6
Taihe Road BDA, Beijing, 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baochang Zhai</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6
Taihe Road BDA, Beijing, 100176, P.R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>⊥</sup>Former employee of AstraZeneca.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4393-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank all of our colleagues at AstraZeneca who were involved in the work reported in this article, encompassing all project team members and functions, including compound purification, compound handling, and technical support from the in vivo sciences group at Alderley Park, U.K. (in particular Joanne Wilson, Richard Grant, and Aaron Smith).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i38" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i38"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> Abbreviations Used</h2><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">1-aminobenzotriazole</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IOC</td><td class="NLM_def"><p class="first last">inhibition of catalysis</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">POA</td><td class="NLM_def"><p class="first last">prevention of activation</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lj2uD8f-yvELQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0liHa7FJjpNmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yoon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seger, R.</span><span> </span><span class="NLM_article-title">The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1080/02699050500284218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1080%2F02699050500284218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16393692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=21-44&author=S.+Yoonauthor=R.+Seger&title=The+extracellular+signal-regulated+kinase%3A+multiple+substrates+regulate+diverse+cellular+functions&doi=10.1080%2F02699050500284218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions</span></div><div class="casAuthors">Yoon, Seunghee; Seger, Rony</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-44</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The extracellular signal-regulated kinase (ERK) cascade is a central pathway that transmits signals from many extracellular agents to regulate cellular processes such as proliferation, differentiation, and cell cycle progression.  The signaling via the ERK cascade is mediated by sequential phosphorylation and activation of protein kinases in the different tiers of the cascade.  Although the main core phosphorylation chain of the cascade includes Raf kinases, MEK1/2, ERK1/2 (ERKs) and RSKs, other alternatively spliced forms and distinct components exist in the different tiers, and participate in ERK signaling under specific conditions.  These components enhance the complexity of the ERK cascade and thereby, enable the wide variety of functions that are regulated by it.  Another factor that is important for the dissemination of ERKs' signals is the multiplicity of the cascade's substrates, which include transcription factors, protein kinases and phosphatases, cytoskeletal elements, regulators of apoptosis, and a variety of other signaling-related mols.  About 160 substrates have already been discovered for ERKs, and the list of these substrates, as well as the function and mechanism of activation of representative substrates, are described in the current review.  Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation.  However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis, and apoptosis.  Understanding of these processes may provide a full picture of the distinct, and even opposing cellular processes that are regulated by the ERK cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE2tenNpAU7Vg90H21EOLACvtfcHk0liHa7FJjpNmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP&md5=746d0818f7fc07229673dfdd6b4165b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F02699050500284218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02699050500284218%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSeger%26aufirst%3DR.%26atitle%3DThe%2520extracellular%2520signal-regulated%2520kinase%253A%2520multiple%2520substrates%2520regulate%2520diverse%2520cellular%2520functions%26jtitle%3DGrowth%2520Factors%26date%3D2006%26volume%3D24%26spage%3D21%26epage%3D44%26doi%3D10.1080%2F02699050500284218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Owens, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyse, S. M.</span><span> </span><span class="NLM_article-title">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3213</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fsj.onc.1210412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17496916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3203-3213&author=D.+M.+Owensauthor=S.+M.+Keyse&title=Differential+regulation+of+MAP+kinase+signalling+by+dual-specificity+protein+phosphatases&doi=10.1038%2Fsj.onc.1210412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span></div><div class="casAuthors">Owens, D. M.; Keyse, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3203-3213</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulated dephosphorylation of mitogen-activated protein kinases (MAPKs) plays a key role in detg. the magnitude and duration of kinase activation and hence the physiol. outcome of signaling.  In mammalian cells, an important component of this control is mediated by the differential expression and activities of a family of 10 dual-specificity (Thr/Tyr) MAPK phosphatases (MKPs).  These enzymes share a common structure in which MAPK substrate recognition is detd. by sequences within an amino-terminal non-catalytic domain whereas MAPK binding often leads to a conformational change within the C-terminal catalytic domain resulting in increased enzyme activity.  MKPs can either recognize and inactivate a single class of MAP kinase, as in the specific inactivation of extracellular signal regulated kinase (ERK) by the cytoplasmic phosphatase DUSP6/MKP-3 or can regulate more than one MAPK pathway as illustrated by the ability of DUSP1/MKP-1 to dephosphorylate ERK, c-Jun amino-terminal kinase and p38 in the cell nucleus.  These properties, coupled with transcriptional regulation of MKP expression in response to stimuli that activate MAPK signaling, suggest a complex neg. regulatory network in which individual MAPK activities can be subject to neg. feedback control, but also raise the possibility that signaling through multiple MAPK pathways may be integrated at the level of regulation by MKPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRQreSvWHwbVg90H21EOLACvtfcHk0liHa7FJjpNmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D&md5=02c50290ecf041cb33318272ca5c8024</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210412%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DD.%2BM.%26aulast%3DKeyse%26aufirst%3DS.%2BM.%26atitle%3DDifferential%2520regulation%2520of%2520MAP%2520kinase%2520signalling%2520by%2520dual-specificity%2520protein%2520phosphatases%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3203%26epage%3D3213%26doi%3D10.1038%2Fsj.onc.1210412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Vakiani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">KRAS and BRAF: drug targets and predictive biomarkers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1002/path.2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1002%2Fpath.2796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=220-230&author=E.+Vakianiauthor=D.+B.+Solit&title=KRAS+and+BRAF%3A+drug+targets+and+predictive+biomarkers&doi=10.1002%2Fpath.2796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpath.2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2796%26sid%3Dliteratum%253Aachs%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DKRAS%2520and%2520BRAF%253A%2520drug%2520targets%2520and%2520predictive%2520biomarkers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D220%26epage%3D230%26doi%3D10.1002%2Fpath.2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0lj-4QcW2VJmYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lj-4QcW2VJmYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span> </span><span class="NLM_article-title">Targeting the RAS pathway in melanoma</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.molmed.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.molmed.2011.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=27-35&author=Z.+Jiauthor=K.+T.+Flahertyauthor=H.+Tsao&title=Targeting+the+RAS+pathway+in+melanoma&doi=10.1016%2Fj.molmed.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DTsao%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520RAS%2520pathway%2520in%2520melanoma%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.molmed.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lhhMubSdDGP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utikal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyakas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span> </span><span class="NLM_article-title">METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1056/NEJMoa1203421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowskiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Ouelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=METRIC+Study+Group+Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1203421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0lhhMubSdDGP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DMETRIC%2520Study%2520Group%2520Improved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114%26doi%3D10.1056%2FNEJMoa1203421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagaw, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+Dinunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lg2sOal-bUbKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDinunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span>BioMed Valley Discoveries. BVD-523. <a href="http://biomed-valley.com/portfolio/bvd-523" class="extLink">http://biomed-valley.com/portfolio/bvd-523</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BioMed+Valley+Discoveries.+BVD-523.+http%3A%2F%2Fbiomed-valley.com%2Fportfolio%2Fbvd-523+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsaker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stults, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5660</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00389</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00389" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5650-5660&author=J.+F.+Blakeauthor=M.+Burkardauthor=J.+Chanauthor=H.+Chenauthor=K.+J.+Chouauthor=D.+Diazauthor=D.+A.+Dudleyauthor=J.+J.+Gaudinoauthor=S.+E.+Gouldauthor=J.+Grinaauthor=T.+Hunsakerauthor=L.+Liuauthor=M.+Martinsonauthor=D.+Morenoauthor=L.+Muellerauthor=C.+Orrauthor=P.+Pachecoauthor=A.+Qinauthor=K.+Rasorauthor=L.+Renauthor=K.+Robargeauthor=S.+Shahidi-Lathamauthor=J.+Stultsauthor=F.+Sullivanauthor=W.+Wangauthor=J.+Yinauthor=A.+Zhouauthor=M.+Belvinauthor=M.+Merchantauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+%28S%29-1-%281-%284-Chloro-3-fluorophenyl%29-2-hydroxyethyl%29-4-%282-%28%281-methyl-1H-pyrazol-5-y+l%29amino%29pyrimidin-4-yl%29pyridin-2%281H%29-one+%28GDC-0994%29%2C+an+extracellular+signal-regulated+kinase+1%2F2+%28ERK1%2F2%29+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.6b00389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00389%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChou%26aufirst%3DK.%2BJ.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DHunsaker%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DA.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DStults%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520%2528S%2529-1-%25281-%25284-Chloro-3-fluorophenyl%2529-2-hydroxyethyl%2529-4-%25282-%2528%25281-methyl-1H-pyrazol-5-y%2520l%2529amino%2529pyrimidin-4-yl%2529pyridin-2%25281H%2529-one%2520%2528GDC-0994%2529%252C%2520an%2520extracellular%2520signal-regulated%2520kinase%25201%252F2%2520%2528ERK1%252F2%2529%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5650%26epage%3D5660%26doi%3D10.1021%2Facs.jmedchem.6b00389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span>Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02313012" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02313012</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety+and+PK+Study+of+CC-90003+in+Relapsed%2FRefractory+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02313012+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. <a href="https://clinicaltrials.gov/ct2/show/NCT02711345" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02711345</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase+I+Clinical+Study+With+Investigational+Compound+LTT462+in+Adult+Patients+With+Specific+Advanced+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02711345+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span>First-in-Human Study of KO-947 in Non-Hematological Malignancies. <a href="https://clinicaltrials.gov/ct2/show/NCT03051035" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03051035</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=First-in-Human+Study+of+KO-947+in+Non-Hematological+Malignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03051035+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer. <a href="https://clinicaltrials.gov/ct2/show/NCT02857270" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02857270</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+LY3214996+Administered+Alone+or+in+Combination+With+Other+Agents+in+Participants+With+Advanced%2FMetastatic+Cancer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02857270+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flemington, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopcroft, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renshaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4790</span><span class="NLM_x">–</span> <span class="NLM_lpage">4801</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-guided+design+of+highly+selective+and+potent+covalent+inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0ljzfaUJO3693g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-guided%2520design%2520of%2520highly%2520selective%2520and%2520potent%2520covalent%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span>A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT01875705" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01875705</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Dose-Escalation+Study+of+GDC-0994+in+Patients+With+Locally+Advanced+or+Metastatic+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01875705+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Copeland, R. A.</span> <span class="citation_source-book">Enzymes</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1002%2F0471220639.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=305-317&author=R.+A.+Copeland&title=Enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F0471220639.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471220639.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEnzymes%26pub%3DWiley-VCH%26date%3D2000%26spage%3D305%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cheng, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span><span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lizYGHsQ1tX0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6362</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span><span class="refDoi"> DOI: 10.1021/jm900630q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900630q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6362-6368&author=A.+M.+Aronovauthor=Q.+Tangauthor=G.+Martinez-Botellaauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=N.+P.+Ewingauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=W.+Marklandauthor=M.+N.+Namchukauthor=S.+Nanthakumarauthor=S.+Poondruauthor=J.+Straubauthor=E.+ter+Haarauthor=X.+Xie&title=Structure-guided+design+of+potent+and+selective+pyrimidylpyrrole+inhibitors+of+extracellular+signal-regulated+kinase+%28ERK%29+using+conformational+control&doi=10.1021%2Fjm900630q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm900630q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900630q%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DEwing%26aufirst%3DN.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520potent%2520and%2520selective%2520pyrimidylpyrrole%2520inhibitors%2520of%2520extracellular%2520signal-regulated%2520kinase%2520%2528ERK%2529%2520using%2520conformational%2520control%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6362%26epage%3D6368%26doi%3D10.1021%2Fjm900630q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, E. M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsounas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/nchembio.1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnchembio.1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=25195011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=853-860&author=A.+Chaikuadauthor=E.+M.+C.+Tacconiauthor=J.+Zimmerauthor=Y.+Liangauthor=N.+S.+Grayauthor=M.+Tarsounasauthor=S.+Knapp&title=A+unique+inhibitor+binding+site+in+ERK1%2F2+is+associated+with+slow+binding+kinetics&doi=10.1038%2Fnchembio.1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span></div><div class="casAuthors">Chaikuad, Apirat; M C Tacconi, Eliana; Zimmer, Jutta; Liang, Yanke; Gray, Nathanael S.; Tarsounas, Madalena; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-860</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs.  Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor.  Here we report the structural mechanism for its remarkable selectivity.  In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration.  This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC.  In contrast, structure detn. of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes.  Notably, the new binding mode with ERK1/2 was assocd. with slow binding kinetics in vitro as well as in cell-based assay systems.  The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNjmmeHD_-LVg90H21EOLACvtfcHk0liv1cY9_C8FCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN&md5=b54251bd7486f0df266d8423ae9c627d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1629%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DTacconi%26aufirst%3DE.%2BM.%2BC.%26aulast%3DZimmer%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520unique%2520inhibitor%2520binding%2520site%2520in%2520ERK1%252F2%2520is%2520associated%2520with%2520slow%2520binding%2520kinetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D853%26epage%3D860%26doi%3D10.1038%2Fnchembio.1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>Small-Molecule Drug Discovery Suite, version 2016-3; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.schrodinger.com/" class="extLink">https://www.schrodinger.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Small-Molecule+Drug+Discovery+Suite%2C+version+2016-3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2016%3B+https%3A%2F%2Fwww.schrodinger.com%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall-Molecule%2520Drug%2520Discovery%2520Suite%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bagdanoff, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madiera, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D.</span><span> </span><span class="NLM_article-title">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3792</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.bmcl.2015.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=26259804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3788-3792&author=J.+T.+Bagdanoffauthor=R.+Jainauthor=W.+Hanauthor=S.+Zhuauthor=A.+M.+Madieraauthor=P.+S.+Leeauthor=X.+Maauthor=D.+Poon&title=Tetrahydropyrrolo-diazepenones+as+inhibitors+of+ERK2+kinase&doi=10.1016%2Fj.bmcl.2015.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Jain, Rama; Han, Wooseok; Zhu, Shejin; Madiera, Ann-Marie; Lee, Patrick S.; Ma, Xiaolei; Poon, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3788-3792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase.  The role of fluorination in mitigating microsomal clearance was systematically explored.  Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXEHIlXy0QLVg90H21EOLACvtfcHk0liv1cY9_C8FCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF&md5=d94c52debb8203a3b9e655319ea32754</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DMadiera%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DTetrahydropyrrolo-diazepenones%2520as%2520inhibitors%2520of%2520ERK2%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3788%26epage%3D3792%26doi%3D10.1016%2Fj.bmcl.2015.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span> </span><span class="NLM_article-title">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.2174/138920007780866799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.2174%2F138920007780866799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17584017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=463-479&author=D.+F.+McGinnityauthor=J.+Collingtonauthor=R.+P.+Austinauthor=R.+J.+Riley&title=Evaluation+of+human+pharmacokinetics%2C+therapeutic+dose+and+exposure+predictions+using+marketed+oral+drugs&doi=10.2174%2F138920007780866799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span></div><div class="casAuthors">McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-479</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this article approaches to predict human pharmacokinetics (PK) are discussed and the capability of the exemplified methodologies to est. individual PK parameters and therapeutic dose for a set of marketed oral drugs has been assessed.  For a set of 63 drugs where the min. efficacious concn. (MEC) and human PK were known, the clin. dose was shown to be well predicted or in some cases over-estd. using a simple one-compartment oral PK model.  For a subset of these drugs, in vitro potency against the primary human targets was gathered, and compared to the obsd. MEC.  When cor. for plasma protein binding, the MEC of the majority of compds. was ≤ 3 fold over the resp. in vitro target potency value.  A series of in vitro and in vivo expts. were conducted to predict the human PK parameters.  Metabolic clearance was generally predicted well from human hepatocytes.  Interestingly, for this compd. set, allometry or glomerular filtration rate (GFR) ratio methods appeared to be applicable for renal CL even where CLrenal > GFR.  For ∼90% of compds. studied, the predicted CL using in vitro-in vivo (IVIV) extrapolation together with a CLrenal est., where appropriate, was within 2-fold of that obsd. clin.  Encouragingly vol. of distribution at steady state (Vss) estd. in preclin. species (rat and dog) when cor. for plasma protein binding, predicted human Vss successfully on the majority of occasions - 73% of compds. within 2-fold.  In this lab., absorption estd. from oral rat PK studies was lower than the obsd. human absorption for most drugs, even when soly. and permeability appeared not to be limiting.  Preliminary data indicate absorption in the dog may be more representative of human for compds. absorbed via the transcellular pathway.  Using predicted PK and MEC values estd. from in vitro potency assays there was a good correlation between predicted and obsd. dose.  This anal. suggests that for oral therapies, human PK parameters and clin. dose can be estd. from a consideration of data obtained from in vitro screens using human derived material and in vivo animal studies.  The benefits and limitations of this holistic approach to PK and dose prediction within the drug discovery process are exemplified and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdbfKDFLO_UrVg90H21EOLACvtfcHk0liv1cY9_C8FCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D&md5=765bdc4b870b660e813e36ae3719ddb5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F138920007780866799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866799%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DCollington%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520human%2520pharmacokinetics%252C%2520therapeutic%2520dose%2520and%2520exposure%2520predictions%2520using%2520marketed%2520oral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D463%26epage%3D479%26doi%3D10.2174%2F138920007780866799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0lj0_XWwkSo52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen activated protein kinases</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+Mckayauthor=P.+Martinauthor=S.+Steeleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen+activated+protein+kinases&doi=10.1158%2F1535-7163.MCT-07-0231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0lj0_XWwkSo52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMckay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DSteele%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen%2520activated%2520protein%2520kinases%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2209%26epage%3D2219%26doi%3D10.1158%2F1535-7163.MCT-07-0231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ward, R. A.; Graham, M. A.; Swallow, S.; Jones, C. D.</span>; <span> </span><span class="NLM_article-title">Substituted 3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one derivatives as kinase inhibitors</span>. PCT Int. Appl. WO2016162325A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+A.+Ward&author=M.+A.+Graham&author=S.+Swallow&author=C.+D.+Jones&title=Substituted+3%2C4-dihydropyrrolo%5B1%2C2-a%5Dpyrazin-1%282H%29-one+derivatives+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DSubstituted%25203%252C4-dihydropyrrolo%255B1%252C2-a%255Dpyrazin-1%25282H%2529-one%2520derivatives%2520as%2520kinase%2520inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomason, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkley, T. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trueman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouchet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaheen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumberbatch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaughan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span> </span><span class="NLM_article-title">AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1727</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F1535-7163.MCT-12-1174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23861347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1715-1727&author=S.+A.+Loddickauthor=S.+J.+Rossauthor=A.+G.+Thomasonauthor=D.+M.+Robinsonauthor=G.+E.+Walkerauthor=T.+P.+J.+Dunkleyauthor=S.+R.+Braveauthor=N.+Broadbentauthor=N.+C.+Strattonauthor=D.+Truemanauthor=E.+Mouchetauthor=F.+S.+Shaheenauthor=V.+N.+Jacobsauthor=M.+Cumberbatchauthor=J.+Wilsonauthor=R.+D.+O.+Jonesauthor=R.+H.+Bradburyauthor=A.+Rabowauthor=L.+Gaughanauthor=C.+Womackauthor=S.+T.+Barryauthor=C.+N.+Robsonauthor=S.+E.+Critchlowauthor=S.+R.+Wedgeauthor=A.+N.+Brooks&title=AZD3514%3A+A+small+molecule+that+modulates+androgen+receptor+signaling+and+function+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-12-1174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo</span></div><div class="casAuthors">Loddick, Sarah A.; Ross, Sarah J.; Thomason, Andrew G.; Robinson, David M.; Walker, Graeme E.; Dunkley, Tom P. J.; Brave, Sandra R.; Broadbent, Nicola; Stratton, Natalie C.; Trueman, Dawn; Mouchet, Elizabeth; Shaheen, Fadhel S.; Jacobs, Vivien N.; Cumberbatch, Marie; Wilson, Joanne; Jones, Rhys D. O.; Bradbury, Robert H.; Rabow, Alfred; Gaughan, Luke; Womack, Chris; Barry, Simon T.; Robson, Craig N.; Critchlow, Susan E.; Wedge, Stephen R.; Brooks, A. Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1715-1727</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease.  Here, we describe the biol. characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling.  AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven nuclear translocation of AR and a downregulation of receptor levels, both of which were obsd. in vitro and in vivo.  AZD3514 inhibited testosterone-driven seminal vesicle development in juvenile male rats and the growth of androgen-dependent Dunning R3327H prostate tumors in adult rats.  Furthermore, this class of compd. showed antitumor activity in the HID28 mouse model of CRPC in vivo.  AZD3514 is currently in phase I clin. evaluation.  Mol Cancer Ther; 12(9); 1715-27. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUjB28XcSVrVg90H21EOLACvtfcHk0lgNJaEBzB2QDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI&md5=553f0953189e9e5982a08c7933566ce0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1174%26sid%3Dliteratum%253Aachs%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DRobinson%26aufirst%3DD.%2BM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DDunkley%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DShaheen%26aufirst%3DF.%2BS.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DWomack%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26atitle%3DAZD3514%253A%2520A%2520small%2520molecule%2520that%2520modulates%2520androgen%2520receptor%2520signaling%2520and%2520function%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1715%26epage%3D1727%26doi%3D10.1158%2F1535-7163.MCT-12-1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Guan Wang, Yuqian Zhao, Yao Liu, Dejuan Sun, Yongqi Zhen, Jie Liu, Leilei Fu, Lan Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Liang Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 3976-3995. <a href="https://doi.org/10.1021/acs.jmedchem.9b01896" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BDual-Target%252BInhibitor%252Bof%252BERK1%252Band%252BERK5%252BThat%252BInduces%252BRegulated%252BCell%252BDeath%252Bto%252BOvercome%252BCompensatory%252BMechanism%252Bin%252BSpecific%252BTumor%252BTypes%26aulast%3DWang%26aufirst%3DGuan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14112019%26date%3D05032020%26date%3D20022020%26volume%3D63%26issue%3D8%26spage%3D3976%26epage%3D3995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Mark J. Anderton, Paul Bethel, Jason Breed, Calum Cook, Emma J. Davies, Andrew Dobson, Zhiqiang Dong, Gary Fairley, Paul Farrington, Lyman Feron, Vikki Flemington, Francis D. Gibbons, Mark A. Graham, Ryan Greenwood, Lyndsey Hanson, Philip Hopcroft, Rachel Howells, Julian Hudson, Michael James, Clifford D. Jones, Christopher R. Jones, Yongchao Li, Scott Lamont, Richard Lewis, Nicola Lindsay, James McCabe, Thomas McGuire, Philip Rawlins, Karen Roberts, Linda Sandin, Iain Simpson, Steve Swallow, Jia Tang, Gary Tomkinson, Michael Tonge, Zhenhua Wang, <span class="NLM_string-name hlFld-ContribAuthor">Baochang Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11004-11018. <a href="https://doi.org/10.1021/acs.jmedchem.9b01295" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01295</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01295%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BOral%252BInhibitor%252Bof%252BERK1%25252F2%252B%252528AZD0364%252529%252BThat%252BIs%252BEfficacious%252Bin%252BBoth%252BMonotherapy%252Band%252BCombination%252BTherapy%252Bin%252BModels%252Bof%252BNonsmall%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D25112019%26date%3D11112019%26volume%3D62%26issue%3D24%26spage%3D11004%26epage%3D11018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaodong Dou, Huixia Huang, Yibo Li, Lan Jiang, Yanxing Wang, Hongwei Jin, Ning Jiao, Lihe Zhang, Liangren Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Zhenming Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6645-6664. <a href="https://doi.org/10.1021/acs.jmedchem.9b00537" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00537</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00537%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultistage%252BScreening%252BReveals%252B3-Substituted%252BIndolin-2-one%252BDerivatives%252Bas%252BNovel%252Band%252BIsoform-Selective%252Bc-Jun%252BN-terminal%252BKinase%252B3%252B%252528JNK3%252529%252BInhibitors%25253A%252BImplications%252Bto%252BDrug%252BDiscovery%252Bfor%252BPotential%252BTreatment%252Bof%252BNeurodegenerative%252BDiseases%26aulast%3DDou%26aufirst%3DXiaodong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D15072019%26date%3D03072019%26volume%3D62%26issue%3D14%26spage%3D6645%26epage%3D6664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria Chizhova, Olesya Khoroshilova, Dmitry Dar’in, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Unusually Reactive Cyclic Anhydride Expands the Scope of the Castagnoli–Cushman Reaction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (20)
                                     , 12722-12733. <a href="https://doi.org/10.1021/acs.joc.8b02164" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02164%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DUnusually%252BReactive%252BCyclic%252BAnhydride%252BExpands%252Bthe%252BScope%252Bof%252Bthe%252BCastagnoli%2525E2%252580%252593Cushman%252BReaction%26aulast%3DChizhova%26aufirst%3DMaria%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21082018%26date%3D28092018%26date%3D18092018%26volume%3D83%26issue%3D20%26spage%3D12722%26epage%3D12733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tom D. Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko M. Buck, Megan Cassidy, Juan Castro, Aurélie Courtin, James E. H. Day, Charlotte East, Lynsey Fazal, Brent Graham, Charlotte M. Griffiths-Jones, John F. Lyons, Vanessa Martins, Sandra Muench, Joanne M. Munck, David Norton, Marc O’Reilly, Nick Palmer, Puja Pathuri, Michael Reader, David C. Rees, Sharna J. Rich, Caroline Richardson, Harpreet Saini, Neil T. Thompson, Nicola G. Wallis, Hugh Walton, Nicola E. Wilsher, Alison J.-A. Woolford, Michael Cooke, David Cousin, Stuart Onions, Jonathan Shannon, John Watts, <span class="NLM_string-name hlFld-ContribAuthor">Christopher W. Murray</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (11)
                                     , 4978-4992. <a href="https://doi.org/10.1021/acs.jmedchem.8b00421" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00421%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BDiscovery%252Bof%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%252BInhibitor%252BThat%252BModulates%252Bthe%252BPhosphorylation%252Band%252BCatalytic%252BActivity%252Bof%252BERK1%25252F2%26aulast%3DHeightman%26aufirst%3DTom%2BD.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14032018%26date%3D31052018%26date%3D18052018%26volume%3D61%26issue%3D11%26spage%3D4978%26epage%3D4992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pieterjan  Winant</span>, <span class="hlFld-ContribAuthor ">Tomas  Horsten</span>, <span class="hlFld-ContribAuthor ">Shaiani  Gil de Melo</span>, <span class="hlFld-ContribAuthor ">Flavio  Emery</span>, <span class="hlFld-ContribAuthor ">Wim  Dehaen</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of the Synthetic Strategies toward Dihydropyrrolo[1,2-a]Pyrazinones. </span><span class="cited-content_cbyCitation_journal-name">Organics</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 118-141. <a href="https://doi.org/10.3390/org2020011" title="DOI URL">https://doi.org/10.3390/org2020011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/org2020011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Forg2020011%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganics%26atitle%3DA%252BReview%252Bof%252Bthe%252BSynthetic%252BStrategies%252Btoward%252BDihydropyrrolo%25255B1%25252C2-a%25255DPyrazinones%26aulast%3DWinant%26aufirst%3DPieterjan%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D118%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Yuanzheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Lei  Tao</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Yinglan  Zhao</span>, <span class="hlFld-ContribAuthor ">Youfu  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (2)
                                     , 1051-1075. <a href="https://doi.org/10.1007/s11030-020-10088-0" title="DOI URL">https://doi.org/10.1007/s11030-020-10088-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10088-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10088-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DStructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%252Bof%252BDEL-22379%25253A%252BERK%252Bdimerization%252Binhibitors%252Bwith%252Bincreased%252Bsafety%26aulast%3DYang%26aufirst%3DYang%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D1051%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Emma J.  Davies</span>, <span class="hlFld-ContribAuthor ">David  Robinson</span>, <span class="hlFld-ContribAuthor ">Linda C.  Sandin</span>, <span class="hlFld-ContribAuthor ">Oona  Delpuech</span>, <span class="hlFld-ContribAuthor ">Pei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lyndsey  Hanson</span>, <span class="hlFld-ContribAuthor ">Paul  Farrington</span>, <span class="hlFld-ContribAuthor ">Sigourney  Bell</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Falenta</span>, <span class="hlFld-ContribAuthor ">Francis D.  Gibbons</span>, <span class="hlFld-ContribAuthor ">Nicola  Lindsay</span>, <span class="hlFld-ContribAuthor ">Aaron  Smith</span>, <span class="hlFld-ContribAuthor ">Joanne  Wilson</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">Michael  Tonge</span>, <span class="hlFld-ContribAuthor ">Philip  Hopcroft</span>, <span class="hlFld-ContribAuthor ">Sophie E.  Willis</span>, <span class="hlFld-ContribAuthor ">Martine P.  Roudier</span>, <span class="hlFld-ContribAuthor ">Claire  Rooney</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Coker</span>, <span class="hlFld-ContribAuthor ">Patricia  Jaaks</span>, <span class="hlFld-ContribAuthor ">Mathew J.  Garnett</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Fawell</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Iain  Simpson</span>, <span class="hlFld-ContribAuthor ">Sabina C.  Cosulich</span>, <span class="hlFld-ContribAuthor ">J. Elizabeth  Pease</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
              KRAS
              -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 238-249. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0002" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0002%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAZD0364%252BIs%252Ba%252BPotent%252Band%252BSelective%252BERK1%25252F2%252BInhibitor%252BThat%252BEnhances%252BAntitumor%252BActivity%252Bin%252BKRAS%252B-Mutant%252BTumor%252BModels%252Bwhen%252BCombined%252Bwith%252Bthe%252BMEK%252BInhibitor%25252C%252BSelumetinib%26aulast%3DFlemington%26aufirst%3DVikki%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D238%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nalinee  Pradubyat</span>, <span class="hlFld-ContribAuthor ">Athina  Giannoudis</span>, <span class="hlFld-ContribAuthor ">Taha  Elmetwali</span>, <span class="hlFld-ContribAuthor ">Panupong  Mahalapbutr</span>, <span class="hlFld-ContribAuthor ">Carlo  Palmieri</span>, <span class="hlFld-ContribAuthor ">Chalermchai  Mitrpant</span>, <span class="hlFld-ContribAuthor ">Wannarasmi  Ketchart</span>. </span><span class="cited-content_cbyCitation_article-title">1′-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Planta Medica</span><span> <strong>2021,</strong> <em>339 </em><a href="https://doi.org/10.1055/a-1307-3997" title="DOI URL">https://doi.org/10.1055/a-1307-3997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1307-3997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1307-3997%26sid%3Dliteratum%253Aachs%26jtitle%3DPlanta%2520Medica%26atitle%3D1%2525E2%252580%2525B2-Acetoxychavicol%252BAcetate%252Bfrom%252BAlpinia%252Bgalanga%252BRepresses%252BProliferation%252Band%252BInvasion%25252C%252Band%252BInduces%252BApoptosis%252Bvia%252BHER2-signaling%252Bin%252BEndocrine-Resistant%252BBreast%252BCancer%252BCells%26aulast%3DPradubyat%26aufirst%3DNalinee%26date%3D2021%26date%3D2021%26volume%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Panagis  Filippakopoulos</span>, <span class="hlFld-ContribAuthor ">Martin P.  Schwalm</span>, <span class="hlFld-ContribAuthor ">Carla A.  Ferrer</span>, <span class="hlFld-ContribAuthor ">David H.  Drewry</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 7953. <a href="https://doi.org/10.3390/ijms21217953" title="DOI URL">https://doi.org/10.3390/ijms21217953</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21217953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21217953%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DCrystal%252BStructure%252Band%252BInhibitor%252BIdentifications%252BReveal%252BTargeting%252BOpportunity%252Bfor%252Bthe%252BAtypical%252BMAPK%252BKinase%252BERK3%26aulast%3DSchr%25C3%25B6der%26aufirst%3DMartin%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D7953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Dou</span>, <span class="hlFld-ContribAuthor ">Huixia  Huang</span>, <span class="hlFld-ContribAuthor ">Lan  Jiang</span>, <span class="hlFld-ContribAuthor ">Guiwang  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongwei  Jin</span>, <span class="hlFld-ContribAuthor ">Ning  Jiao</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Lihe  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>201 </em>, 112445. <a href="https://doi.org/10.1016/j.ejmech.2020.112445" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112445%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bmodification%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C4-dihydroquinoxalin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252Bc-Jun%252BN-terminal%252Bkinase%252B3%252B%252528JNK3%252529%252Binhibitors%26aulast%3DDou%26aufirst%3DXiaodong%26date%3D2020%26volume%3D201%26spage%3D112445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ewa  Jasek-Gajda</span>, <span class="hlFld-ContribAuthor ">Halina  Jurkowska</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Jasińska</span>, <span class="hlFld-ContribAuthor ">Grzegorz J.  Lis</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2020,</strong> <em>9 </em>
                                    (7)
                                     , 633. <a href="https://doi.org/10.3390/antiox9070633" title="DOI URL">https://doi.org/10.3390/antiox9070633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox9070633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox9070633%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DTargeting%252Bthe%252BMAPK%25252FERK%252Band%252BPI3K%25252FAKT%252BSignaling%252BPathways%252BAffects%252BNRF2%25252C%252BTrx%252Band%252BGSH%252BAntioxidant%252BSystems%252Bin%252BLeukemia%252BCells%26aulast%3DJasek-Gajda%26aufirst%3DEwa%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D7%26spage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelly  Pathania</span>, <span class="hlFld-ContribAuthor ">Ravindra K  Rawal</span>. </span><span class="cited-content_cbyCitation_article-title">An update on chemical classes targeting ERK1/2 for the management of cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em><a href="https://doi.org/10.4155/fmc-2019-0339" title="DOI URL">https://doi.org/10.4155/fmc-2019-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bon%252Bchemical%252Bclasses%252Btargeting%252BERK1%25252F2%252Bfor%252Bthe%252Bmanagement%252Bof%252Bcancer%26aulast%3DPathania%26aufirst%3DShelly%26date%3D2020%26date%3D2020%26volume%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longfei  Miao</span>, <span class="hlFld-ContribAuthor ">Hongqi  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2020,</strong> <em>28 </em>
                                    (2)
                                     , 154-165. <a href="https://doi.org/10.1080/1061186X.2019.1648477" title="DOI URL">https://doi.org/10.1080/1061186X.2019.1648477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2019.1648477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2019.1648477%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DDevelopment%252Bof%252BERK1%25252F2%252Binhibitors%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Btumour%252Bwith%252BMAPK%252Bupstream%252Btarget%252Bmutations%26aulast%3DMiao%26aufirst%3DLongfei%26date%3D2020%26date%3D2019%26volume%3D28%26issue%3D2%26spage%3D154%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">Joanne M.  Munck</span>, <span class="hlFld-ContribAuthor ">Harpreet K.  Saini</span>, <span class="hlFld-ContribAuthor ">Kathryn  Balmanno</span>, <span class="hlFld-ContribAuthor ">Emma  Minihane</span>, <span class="hlFld-ContribAuthor ">Aurelie  Courtin</span>, <span class="hlFld-ContribAuthor ">Brent  Graham</span>, <span class="hlFld-ContribAuthor ">Marc  O'Reilly</span>, <span class="hlFld-ContribAuthor ">Richard  Odle</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (2)
                                     , 525-539. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0505" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0505%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DDual-Mechanism%252BERK1%25252F2%252BInhibitors%252BExploit%252Ba%252BDistinct%252BBinding%252BMode%252Bto%252BBlock%252BPhosphorylation%252Band%252BNuclear%252BAccumulation%252Bof%252BERK1%25252F2%26aulast%3DKidger%26aufirst%3DAndrew%2BM.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D2%26spage%3D525%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew J.  Sale</span>, <span class="hlFld-ContribAuthor ">Emma  Minihane</span>, <span class="hlFld-ContribAuthor ">Noel R.  Monks</span>, <span class="hlFld-ContribAuthor ">Rebecca  Gilley</span>, <span class="hlFld-ContribAuthor ">Frances M.  Richards</span>, <span class="hlFld-ContribAuthor ">Kevin P.  Schifferli</span>, <span class="hlFld-ContribAuthor ">Courtney L.  Andersen</span>, <span class="hlFld-ContribAuthor ">Emma J.  Davies</span>, <span class="hlFld-ContribAuthor ">Mario Aladren  Vicente</span>, <span class="hlFld-ContribAuthor ">Eiko  Ozono</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Markovets</span>, <span class="hlFld-ContribAuthor ">Jonathan R.  Dry</span>, <span class="hlFld-ContribAuthor ">Lisa  Drew</span>, <span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Theresa  Proia</span>, <span class="hlFld-ContribAuthor ">Duncan I.  Jodrell</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-12409-w" title="DOI URL">https://doi.org/10.1038/s41467-019-12409-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-12409-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-12409-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DTargeting%252Bmelanoma%2525E2%252580%252599s%252BMCL1%252Bbias%252Bunleashes%252Bthe%252Bapoptotic%252Bpotential%252Bof%252BBRAF%252Band%252BERK1%25252F2%252Bpathway%252Binhibitors%26aulast%3DSale%26aufirst%3DMatthew%2BJ.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Selim</span>, <span class="hlFld-ContribAuthor ">Elgazar</span>, <span class="hlFld-ContribAuthor ">Abdel-Hamid</span>, <span class="hlFld-ContribAuthor ">El-Magd</span>, <span class="hlFld-ContribAuthor ">Yasri</span>, <span class="hlFld-ContribAuthor ">Hefnawy</span>, <span class="hlFld-ContribAuthor ">Sobeh</span>. </span><span class="cited-content_cbyCitation_article-title">Chrysophanol, Physcion, Hesperidin and Curcumin Modulate the Gene Expression of Pro-Inflammatory Mediators Induced by LPS in HepG2: In Silico and Molecular Studies. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 371. <a href="https://doi.org/10.3390/antiox8090371" title="DOI URL">https://doi.org/10.3390/antiox8090371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox8090371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox8090371%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DChrysophanol%25252C%252BPhyscion%25252C%252BHesperidin%252Band%252BCurcumin%252BModulate%252Bthe%252BGene%252BExpression%252Bof%252BPro-Inflammatory%252BMediators%252BInduced%252Bby%252BLPS%252Bin%252BHepG2%25253A%252BIn%252BSilico%252Band%252BMolecular%252BStudies%26aulast%3DSelim%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiyi  Xiong</span>, <span class="hlFld-ContribAuthor ">Yanfang  Yang</span>, <span class="hlFld-ContribAuthor ">Weichen  Xiong</span>, <span class="hlFld-ContribAuthor ">Yunfeng  Yao</span>, <span class="hlFld-ContribAuthor ">Hezhen  Wu</span>, <span class="hlFld-ContribAuthor ">Meide  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Network pharmacology‐based research on the active component and mechanism of the antihepatoma effect of
              Rubia cordifolia
              L.. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2019,</strong> <em>120 </em>
                                    (8)
                                     , 12461-12472. <a href="https://doi.org/10.1002/jcb.28513" title="DOI URL">https://doi.org/10.1002/jcb.28513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.28513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.28513%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DNetwork%252Bpharmacology%2525E2%252580%252590based%252Bresearch%252Bon%252Bthe%252Bactive%252Bcomponent%252Band%252Bmechanism%252Bof%252Bthe%252Bantihepatoma%252Beffect%252Bof%252BRubia%252Bcordifolia%252BL.%26aulast%3DXiong%26aufirst%3DYiyi%26date%3D2019%26date%3D2019%26volume%3D120%26issue%3D8%26spage%3D12461%26epage%3D12472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monserrat  Olea-Flores</span>, <span class="hlFld-ContribAuthor ">Miriam Daniela  Zuñiga-Eulogio</span>, <span class="hlFld-ContribAuthor ">Miguel Angel  Mendoza-Catalán</span>, <span class="hlFld-ContribAuthor ">Hugo Alberto  Rodríguez-Ruiz</span>, <span class="hlFld-ContribAuthor ">Eduardo  Castañeda-Saucedo</span>, <span class="hlFld-ContribAuthor ">Carlos  Ortuño-Pineda</span>, <span class="hlFld-ContribAuthor ">Teresita  Padilla-Benavides</span>, <span class="hlFld-ContribAuthor ">Napoleón  Navarro-Tito</span>. </span><span class="cited-content_cbyCitation_article-title">Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (12)
                                     , 2885. <a href="https://doi.org/10.3390/ijms20122885" title="DOI URL">https://doi.org/10.3390/ijms20122885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20122885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20122885%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DExtracellular-Signal%252BRegulated%252BKinase%25253A%252BA%252BCentral%252BMolecule%252BDriving%252BEpithelial%2525E2%252580%252593Mesenchymal%252BTransition%252Bin%252BCancer%26aulast%3DOlea-Flores%26aufirst%3DMonserrat%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D12%26spage%3D2885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isabella Mary Alves  Reis</span>, <span class="hlFld-ContribAuthor ">Rodrigo Souza  Conceição</span>, <span class="hlFld-ContribAuthor ">Rafael Short  Ferreira</span>, <span class="hlFld-ContribAuthor ">Cleonice Creusa  dos Santos</span>, <span class="hlFld-ContribAuthor ">Girliane Regina  da Silva</span>, <span class="hlFld-ContribAuthor ">Larissa  de Mattos Oliveira</span>, <span class="hlFld-ContribAuthor ">Dayse Santos Almeida  Cassiano</span>, <span class="hlFld-ContribAuthor ">Manoelito Coelho  dos Santos Junior</span>, <span class="hlFld-ContribAuthor ">Mariana Borges  Botura</span>, <span class="hlFld-ContribAuthor ">Victor Diogenes Amaral  da Silva</span>, <span class="hlFld-ContribAuthor ">Silvia Lima  Costa</span>, <span class="hlFld-ContribAuthor ">Tania Maria Sarmento  da Silva</span>, <span class="hlFld-ContribAuthor ">Ivo José Curcino  Vieira</span>, <span class="hlFld-ContribAuthor ">Raimundo  Braz-Filho</span>, <span class="hlFld-ContribAuthor ">Alexsandro  Branco</span>. </span><span class="cited-content_cbyCitation_article-title">Alkene lactones from Persea fulva (Lauraceae): Evaluation of their effects on tumor cell growth in vitro and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>86 </em>, 665-673. <a href="https://doi.org/10.1016/j.bioorg.2019.02.023" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.02.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.02.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAlkene%252Blactones%252Bfrom%252BPersea%252Bfulva%252B%252528Lauraceae%252529%25253A%252BEvaluation%252Bof%252Btheir%252Beffects%252Bon%252Btumor%252Bcell%252Bgrowth%252Bin%252Bvitro%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DReis%26aufirst%3DIsabella%2BMary%2BAlves%26date%3D2019%26volume%3D86%26spage%3D665%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph  Shaw</span>, <span class="hlFld-ContribAuthor ">Ian  Dale</span>, <span class="hlFld-ContribAuthor ">Paul  Hemsley</span>, <span class="hlFld-ContribAuthor ">Lindsey  Leach</span>, <span class="hlFld-ContribAuthor ">Nancy  Dekki</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  Orme</span>, <span class="hlFld-ContribAuthor ">Verity  Talbot</span>, <span class="hlFld-ContribAuthor ">Ana J.  Narvaez</span>, <span class="hlFld-ContribAuthor ">Michal  Bista</span>, <span class="hlFld-ContribAuthor ">Daniel  Martinez Molina</span>, <span class="hlFld-ContribAuthor ">Michael  Dabrowski</span>, <span class="hlFld-ContribAuthor ">Martin J.  Main</span>, <span class="hlFld-ContribAuthor ">Davide  Gianni</span>. </span><span class="cited-content_cbyCitation_article-title">Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2019,</strong> <em>24 </em>
                                    (2)
                                     , 121-132. <a href="https://doi.org/10.1177/2472555218813332" title="DOI URL">https://doi.org/10.1177/2472555218813332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555218813332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555218813332%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DPositioning%252BHigh-Throughput%252BCETSA%252Bin%252BEarly%252BDrug%252BDiscovery%252Bthrough%252BScreening%252Bagainst%252BB-Raf%252Band%252BPARP1%26aulast%3DShaw%26aufirst%3DJoseph%26date%3D2019%26date%3D2018%26volume%3D24%26issue%3D2%26spage%3D121%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Caroline Anne  McMillan</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis of novel 1,2,6,7-tetrahydro-3H-pyrazolo[4,3-c]pyridine-3,4(5H)-diones. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (39)
                                     , 3574-3578. <a href="https://doi.org/10.1016/j.tetlet.2018.08.036" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.08.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.08.036%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DOne-pot%252Bsynthesis%252Bof%252Bnovel%252B1%25252C2%25252C6%25252C7-tetrahydro-3H-pyrazolo%25255B4%25252C3-c%25255Dpyridine-3%25252C4%2525285H%252529-diones%26aulast%3DFairley%26aufirst%3DGary%26date%3D2018%26volume%3D59%26issue%3D39%26spage%3D3574%26epage%3D3578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdullah A.  Elgazar</span>, <span class="hlFld-ContribAuthor ">Nabil M.  Selim</span>, <span class="hlFld-ContribAuthor ">Nabil M.  Abdel-Hamid</span>, <span class="hlFld-ContribAuthor ">Mohammed A.  El-Magd</span>, <span class="hlFld-ContribAuthor ">Hala M.  El Hefnawy</span>. </span><span class="cited-content_cbyCitation_article-title">Isolates from
              Alpinia officinarum
              Hance attenuate LPS-induced inflammation in HepG2: Evidence from
              in silico
              and
              in vitro
              studies. </span><span class="cited-content_cbyCitation_journal-name">Phytotherapy Research</span><span> <strong>2018,</strong> <em>32 </em>
                                    (7)
                                     , 1273-1288. <a href="https://doi.org/10.1002/ptr.6056" title="DOI URL">https://doi.org/10.1002/ptr.6056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ptr.6056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fptr.6056%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytotherapy%2520Research%26atitle%3DIsolates%252Bfrom%252BAlpinia%252Bofficinarum%252BHance%252Battenuate%252BLPS-induced%252Binflammation%252Bin%252BHepG2%25253A%252BEvidence%252Bfrom%252Bin%252Bsilico%252Band%252Bin%252Bvitro%252Bstudies%26aulast%3DElgazar%26aufirst%3DAbdullah%2BA.%26date%3D2018%26date%3D2018%26volume%3D32%26issue%3D7%26spage%3D1273%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">James  Sipthorp</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>187 </em>, 45-60. <a href="https://doi.org/10.1016/j.pharmthera.2018.02.007" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2018.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2018.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2018.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DERK1%25252F2%252Binhibitors%25253A%252BNew%252Bweapons%252Bto%252Binhibit%252Bthe%252BRAS-regulated%252BRAF-MEK1%25252F2-ERK1%25252F2%252Bpathway%26aulast%3DKidger%26aufirst%3DAndrew%2BM.%26date%3D2018%26volume%3D187%26spage%3D45%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Didier  Decaudin</span>, <span class="hlFld-ContribAuthor ">Rania  El Botty</span>, <span class="hlFld-ContribAuthor ">Béré  Diallo</span>, <span class="hlFld-ContribAuthor ">Gerald  Massonnet</span>, <span class="hlFld-ContribAuthor ">Justine  Fleury</span>, <span class="hlFld-ContribAuthor ">Adnan  Naguez</span>, <span class="hlFld-ContribAuthor ">Chloé  Raymondie</span>, <span class="hlFld-ContribAuthor ">Emma  Davies</span>, <span class="hlFld-ContribAuthor ">Aaron  Smith</span>, <span class="hlFld-ContribAuthor ">Joanne  Wilson</span>, <span class="hlFld-ContribAuthor ">Colin  Howes</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>, <span class="hlFld-ContribAuthor ">Nathalie  Cassoux</span>, <span class="hlFld-ContribAuthor ">Sophie  Piperno-Neumann</span>, <span class="hlFld-ContribAuthor ">Sergio  Roman-Roman</span>, <span class="hlFld-ContribAuthor ">Fariba  Némati</span>. </span><span class="cited-content_cbyCitation_article-title">Selumetinib-based therapy in uveal melanoma patient-derived xenografts. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (31)
                                     , 21674-21686. <a href="https://doi.org/10.18632/oncotarget.24670" title="DOI URL">https://doi.org/10.18632/oncotarget.24670</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.24670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.24670%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DSelumetinib-based%252Btherapy%252Bin%252Buveal%252Bmelanoma%252Bpatient-derived%252Bxenografts%26aulast%3DDecaudin%26aufirst%3DDidier%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D31%26spage%3D21674%26epage%3D21686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raju  Cheerlavancha</span>, <span class="hlFld-ContribAuthor ">Ahmed  Ahmed</span>, <span class="hlFld-ContribAuthor ">Yun Cheuk  Leung</span>, <span class="hlFld-ContribAuthor ">Aggie  Lawer</span>, <span class="hlFld-ContribAuthor ">Qing-Quan  Liu</span>, <span class="hlFld-ContribAuthor ">Marina  Cagnes</span>, <span class="hlFld-ContribAuthor ">Hee-Chan  Jang</span>, <span class="hlFld-ContribAuthor ">Xiang-Guo  Hu</span>, <span class="hlFld-ContribAuthor ">Luke  Hunter</span>. </span><span class="cited-content_cbyCitation_article-title">Homologated amino acids with three vicinal fluorines positioned along the backbone: development of a stereoselective synthesis. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>13 </em>, 2316-2325. <a href="https://doi.org/10.3762/bjoc.13.228" title="DOI URL">https://doi.org/10.3762/bjoc.13.228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.13.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.13.228%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DHomologated%252Bamino%252Bacids%252Bwith%252Bthree%252Bvicinal%252Bfluorines%252Bpositioned%252Balong%252Bthe%252Bbackbone%25253A%252Bdevelopment%252Bof%252Ba%252Bstereoselective%252Bsynthesis%26aulast%3DCheerlavancha%26aufirst%3DRaju%26date%3D2017%26date%3D2017%26volume%3D13%26spage%3D2316%26epage%3D2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of published ERK1/2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (top) Binding mode of <b>4</b> elucidated in the human ERK2 crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU">5NGU</a>). (middle) Binding mode of published inhibitor <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I60">3I60</a>). (bottom) Overlay of the structures of inhibitors <b>4</b> and <b>5</b>. This and similar figures were prepared using Schrödinger Maestro, version 2016-3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>4</b> elucidated in the human ERK2 crystal structure (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU">5NGU</a>) overlaid with <b>8</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHF">5NHF</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (left) Binding mode of <b>12</b> elucidated in the human ERK2 crystal structure (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH">5NHH</a>) overlaid with <b>14</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHJ">5NHJ</a>). (right) Binding mode of <b>17</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHL">5NHL</a>) overlaid with <b>18</b> (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHO">5NHO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>22</b> elucidated in the human ERK2 crystal structure (brown, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP">5NHP</a>) overlaid with compound <b>12</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH">5NHH</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. QM torsion profile of an alternative pyrrolopyrazinone ring system (<b>C</b>) compared with those of pyrrololactam cores <b>A</b> and <b>B</b>. Gas-phase energies (in kcal/mol) were calculated in Jaguar (Maestro version 2016-3, Schrödinger) using a relaxed coordinate scan with an increment of 5° (d) using density functional theory with the B3LYP functional and the 6-31G** basis set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, water, 80 °C, 64%; (ii) HCl, 1,4-dioxane, MeOH, 99%; (iii) K<sub>2</sub>CO<sub>3</sub>, 18-crown-6, 1,4-dioxane, 100 °C, 93%; (iv) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 22 °C, then NH<sub>3</sub>, MeOH, 22 °C, 95%; (v) NaH, DMF, 20 °C, 83%; (vi) third-generation BrettPhos precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, <i>t-</i>BuOH, 80 °C, 77%.</p></p></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (left) Free plasma concentrations in nude mice following 100 mg/kg daily oral dose of <b>35</b> in relation to cover over pRSK IC<sub>50</sub>. (right) PK properties and early dose to human predictions for <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PD evaluation of <b>35</b> in the Calu-6 in vivo model of NSCLC. The bar charts show average percent pRSK expression normalized to vehicle controls over time. The line charts show average concentration of free drug (PK) over time. Error bars show ±SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/medium/jm-2017-002677_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor efficacy of <b>35</b> in the Calu-6 NSCLC model. The plots show average tumor volume of Calu-6 over time upon treatment with an oral formulation of <b>35</b> at 5, 15, or 50 mg/kg Q.D. Average volumes are geomeans, and error bars show ±SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.7b00267/20170421/images/large/jm-2017-002677_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00267&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34586" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34586" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0ljotZXiHnhwrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lickI1PHRecXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yoon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seger, R.</span><span> </span><span class="NLM_article-title">The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1080/02699050500284218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1080%2F02699050500284218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16393692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=21-44&author=S.+Yoonauthor=R.+Seger&title=The+extracellular+signal-regulated+kinase%3A+multiple+substrates+regulate+diverse+cellular+functions&doi=10.1080%2F02699050500284218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions</span></div><div class="casAuthors">Yoon, Seunghee; Seger, Rony</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-44</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The extracellular signal-regulated kinase (ERK) cascade is a central pathway that transmits signals from many extracellular agents to regulate cellular processes such as proliferation, differentiation, and cell cycle progression.  The signaling via the ERK cascade is mediated by sequential phosphorylation and activation of protein kinases in the different tiers of the cascade.  Although the main core phosphorylation chain of the cascade includes Raf kinases, MEK1/2, ERK1/2 (ERKs) and RSKs, other alternatively spliced forms and distinct components exist in the different tiers, and participate in ERK signaling under specific conditions.  These components enhance the complexity of the ERK cascade and thereby, enable the wide variety of functions that are regulated by it.  Another factor that is important for the dissemination of ERKs' signals is the multiplicity of the cascade's substrates, which include transcription factors, protein kinases and phosphatases, cytoskeletal elements, regulators of apoptosis, and a variety of other signaling-related mols.  About 160 substrates have already been discovered for ERKs, and the list of these substrates, as well as the function and mechanism of activation of representative substrates, are described in the current review.  Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation.  However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis, and apoptosis.  Understanding of these processes may provide a full picture of the distinct, and even opposing cellular processes that are regulated by the ERK cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE2tenNpAU7Vg90H21EOLACvtfcHk0lickI1PHRecXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP&md5=746d0818f7fc07229673dfdd6b4165b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F02699050500284218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02699050500284218%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSeger%26aufirst%3DR.%26atitle%3DThe%2520extracellular%2520signal-regulated%2520kinase%253A%2520multiple%2520substrates%2520regulate%2520diverse%2520cellular%2520functions%26jtitle%3DGrowth%2520Factors%26date%3D2006%26volume%3D24%26spage%3D21%26epage%3D44%26doi%3D10.1080%2F02699050500284218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Owens, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyse, S. M.</span><span> </span><span class="NLM_article-title">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3213</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fsj.onc.1210412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17496916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3203-3213&author=D.+M.+Owensauthor=S.+M.+Keyse&title=Differential+regulation+of+MAP+kinase+signalling+by+dual-specificity+protein+phosphatases&doi=10.1038%2Fsj.onc.1210412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span></div><div class="casAuthors">Owens, D. M.; Keyse, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3203-3213</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulated dephosphorylation of mitogen-activated protein kinases (MAPKs) plays a key role in detg. the magnitude and duration of kinase activation and hence the physiol. outcome of signaling.  In mammalian cells, an important component of this control is mediated by the differential expression and activities of a family of 10 dual-specificity (Thr/Tyr) MAPK phosphatases (MKPs).  These enzymes share a common structure in which MAPK substrate recognition is detd. by sequences within an amino-terminal non-catalytic domain whereas MAPK binding often leads to a conformational change within the C-terminal catalytic domain resulting in increased enzyme activity.  MKPs can either recognize and inactivate a single class of MAP kinase, as in the specific inactivation of extracellular signal regulated kinase (ERK) by the cytoplasmic phosphatase DUSP6/MKP-3 or can regulate more than one MAPK pathway as illustrated by the ability of DUSP1/MKP-1 to dephosphorylate ERK, c-Jun amino-terminal kinase and p38 in the cell nucleus.  These properties, coupled with transcriptional regulation of MKP expression in response to stimuli that activate MAPK signaling, suggest a complex neg. regulatory network in which individual MAPK activities can be subject to neg. feedback control, but also raise the possibility that signaling through multiple MAPK pathways may be integrated at the level of regulation by MKPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRQreSvWHwbVg90H21EOLACvtfcHk0ljj-AAMvAZ6og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D&md5=02c50290ecf041cb33318272ca5c8024</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210412%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DD.%2BM.%26aulast%3DKeyse%26aufirst%3DS.%2BM.%26atitle%3DDifferential%2520regulation%2520of%2520MAP%2520kinase%2520signalling%2520by%2520dual-specificity%2520protein%2520phosphatases%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3203%26epage%3D3213%26doi%3D10.1038%2Fsj.onc.1210412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Vakiani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">KRAS and BRAF: drug targets and predictive biomarkers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1002/path.2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1002%2Fpath.2796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=220-230&author=E.+Vakianiauthor=D.+B.+Solit&title=KRAS+and+BRAF%3A+drug+targets+and+predictive+biomarkers&doi=10.1002%2Fpath.2796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpath.2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2796%26sid%3Dliteratum%253Aachs%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DKRAS%2520and%2520BRAF%253A%2520drug%2520targets%2520and%2520predictive%2520biomarkers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D220%26epage%3D230%26doi%3D10.1002%2Fpath.2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0ljj-AAMvAZ6og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgGEPtcu1Qstw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span> </span><span class="NLM_article-title">Targeting the RAS pathway in melanoma</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.molmed.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.molmed.2011.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=27-35&author=Z.+Jiauthor=K.+T.+Flahertyauthor=H.+Tsao&title=Targeting+the+RAS+pathway+in+melanoma&doi=10.1016%2Fj.molmed.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DTsao%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520RAS%2520pathway%2520in%2520melanoma%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.molmed.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lgGEPtcu1Qstw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utikal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyakas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span> </span><span class="NLM_article-title">METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1056/NEJMoa1203421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowskiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Ouelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=METRIC+Study+Group+Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1203421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0liAlvgVkQkUTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DMETRIC%2520Study%2520Group%2520Improved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114%26doi%3D10.1056%2FNEJMoa1203421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagaw, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+Dinunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0liUnYiFp13cVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDinunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span>BioMed Valley Discoveries. BVD-523. <a href="http://biomed-valley.com/portfolio/bvd-523" class="extLink">http://biomed-valley.com/portfolio/bvd-523</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BioMed+Valley+Discoveries.+BVD-523.+http%3A%2F%2Fbiomed-valley.com%2Fportfolio%2Fbvd-523+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsaker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stults, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5660</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00389</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00389" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5650-5660&author=J.+F.+Blakeauthor=M.+Burkardauthor=J.+Chanauthor=H.+Chenauthor=K.+J.+Chouauthor=D.+Diazauthor=D.+A.+Dudleyauthor=J.+J.+Gaudinoauthor=S.+E.+Gouldauthor=J.+Grinaauthor=T.+Hunsakerauthor=L.+Liuauthor=M.+Martinsonauthor=D.+Morenoauthor=L.+Muellerauthor=C.+Orrauthor=P.+Pachecoauthor=A.+Qinauthor=K.+Rasorauthor=L.+Renauthor=K.+Robargeauthor=S.+Shahidi-Lathamauthor=J.+Stultsauthor=F.+Sullivanauthor=W.+Wangauthor=J.+Yinauthor=A.+Zhouauthor=M.+Belvinauthor=M.+Merchantauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+%28S%29-1-%281-%284-Chloro-3-fluorophenyl%29-2-hydroxyethyl%29-4-%282-%28%281-methyl-1H-pyrazol-5-y+l%29amino%29pyrimidin-4-yl%29pyridin-2%281H%29-one+%28GDC-0994%29%2C+an+extracellular+signal-regulated+kinase+1%2F2+%28ERK1%2F2%29+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.6b00389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00389%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChou%26aufirst%3DK.%2BJ.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DHunsaker%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DA.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DStults%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520%2528S%2529-1-%25281-%25284-Chloro-3-fluorophenyl%2529-2-hydroxyethyl%2529-4-%25282-%2528%25281-methyl-1H-pyrazol-5-y%2520l%2529amino%2529pyrimidin-4-yl%2529pyridin-2%25281H%2529-one%2520%2528GDC-0994%2529%252C%2520an%2520extracellular%2520signal-regulated%2520kinase%25201%252F2%2520%2528ERK1%252F2%2529%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5650%26epage%3D5660%26doi%3D10.1021%2Facs.jmedchem.6b00389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span>Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02313012" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02313012</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety+and+PK+Study+of+CC-90003+in+Relapsed%2FRefractory+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02313012+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. <a href="https://clinicaltrials.gov/ct2/show/NCT02711345" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02711345</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase+I+Clinical+Study+With+Investigational+Compound+LTT462+in+Adult+Patients+With+Specific+Advanced+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02711345+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span>First-in-Human Study of KO-947 in Non-Hematological Malignancies. <a href="https://clinicaltrials.gov/ct2/show/NCT03051035" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03051035</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=First-in-Human+Study+of+KO-947+in+Non-Hematological+Malignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03051035+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer. <a href="https://clinicaltrials.gov/ct2/show/NCT02857270" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02857270</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+LY3214996+Administered+Alone+or+in+Combination+With+Other+Agents+in+Participants+With+Advanced%2FMetastatic+Cancer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02857270+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flemington, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopcroft, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renshaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4790</span><span class="NLM_x">–</span> <span class="NLM_lpage">4801</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-guided+design+of+highly+selective+and+potent+covalent+inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0ljPczdMDXbWYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-guided%2520design%2520of%2520highly%2520selective%2520and%2520potent%2520covalent%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span>A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT01875705" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01875705</a> (accessed March 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Dose-Escalation+Study+of+GDC-0994+in+Patients+With+Locally+Advanced+or+Metastatic+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01875705+%28accessed+March+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Copeland, R. A.</span> <span class="citation_source-book">Enzymes</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1002%2F0471220639.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=305-317&author=R.+A.+Copeland&title=Enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F0471220639.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471220639.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEnzymes%26pub%3DWiley-VCH%26date%3D2000%26spage%3D305%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cheng, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span><span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhBYGWyeXT_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6362</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span><span class="refDoi"> DOI: 10.1021/jm900630q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900630q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6362-6368&author=A.+M.+Aronovauthor=Q.+Tangauthor=G.+Martinez-Botellaauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=N.+P.+Ewingauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=W.+Marklandauthor=M.+N.+Namchukauthor=S.+Nanthakumarauthor=S.+Poondruauthor=J.+Straubauthor=E.+ter+Haarauthor=X.+Xie&title=Structure-guided+design+of+potent+and+selective+pyrimidylpyrrole+inhibitors+of+extracellular+signal-regulated+kinase+%28ERK%29+using+conformational+control&doi=10.1021%2Fjm900630q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm900630q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900630q%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DEwing%26aufirst%3DN.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520potent%2520and%2520selective%2520pyrimidylpyrrole%2520inhibitors%2520of%2520extracellular%2520signal-regulated%2520kinase%2520%2528ERK%2529%2520using%2520conformational%2520control%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6362%26epage%3D6368%26doi%3D10.1021%2Fjm900630q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, E. M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsounas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/nchembio.1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnchembio.1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=25195011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=853-860&author=A.+Chaikuadauthor=E.+M.+C.+Tacconiauthor=J.+Zimmerauthor=Y.+Liangauthor=N.+S.+Grayauthor=M.+Tarsounasauthor=S.+Knapp&title=A+unique+inhibitor+binding+site+in+ERK1%2F2+is+associated+with+slow+binding+kinetics&doi=10.1038%2Fnchembio.1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span></div><div class="casAuthors">Chaikuad, Apirat; M C Tacconi, Eliana; Zimmer, Jutta; Liang, Yanke; Gray, Nathanael S.; Tarsounas, Madalena; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-860</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs.  Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor.  Here we report the structural mechanism for its remarkable selectivity.  In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration.  This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC.  In contrast, structure detn. of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes.  Notably, the new binding mode with ERK1/2 was assocd. with slow binding kinetics in vitro as well as in cell-based assay systems.  The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNjmmeHD_-LVg90H21EOLACvtfcHk0lhBYGWyeXT_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN&md5=b54251bd7486f0df266d8423ae9c627d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1629%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DTacconi%26aufirst%3DE.%2BM.%2BC.%26aulast%3DZimmer%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520unique%2520inhibitor%2520binding%2520site%2520in%2520ERK1%252F2%2520is%2520associated%2520with%2520slow%2520binding%2520kinetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D853%26epage%3D860%26doi%3D10.1038%2Fnchembio.1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>Small-Molecule Drug Discovery Suite, version 2016-3; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.schrodinger.com/" class="extLink">https://www.schrodinger.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Small-Molecule+Drug+Discovery+Suite%2C+version+2016-3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2016%3B+https%3A%2F%2Fwww.schrodinger.com%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall-Molecule%2520Drug%2520Discovery%2520Suite%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bagdanoff, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madiera, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D.</span><span> </span><span class="NLM_article-title">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3792</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1016%2Fj.bmcl.2015.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=26259804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3788-3792&author=J.+T.+Bagdanoffauthor=R.+Jainauthor=W.+Hanauthor=S.+Zhuauthor=A.+M.+Madieraauthor=P.+S.+Leeauthor=X.+Maauthor=D.+Poon&title=Tetrahydropyrrolo-diazepenones+as+inhibitors+of+ERK2+kinase&doi=10.1016%2Fj.bmcl.2015.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Jain, Rama; Han, Wooseok; Zhu, Shejin; Madiera, Ann-Marie; Lee, Patrick S.; Ma, Xiaolei; Poon, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3788-3792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase.  The role of fluorination in mitigating microsomal clearance was systematically explored.  Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXEHIlXy0QLVg90H21EOLACvtfcHk0ljnJ-GYPeJ8pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF&md5=d94c52debb8203a3b9e655319ea32754</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DMadiera%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DTetrahydropyrrolo-diazepenones%2520as%2520inhibitors%2520of%2520ERK2%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3788%26epage%3D3792%26doi%3D10.1016%2Fj.bmcl.2015.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span> </span><span class="NLM_article-title">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.2174/138920007780866799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.2174%2F138920007780866799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17584017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=463-479&author=D.+F.+McGinnityauthor=J.+Collingtonauthor=R.+P.+Austinauthor=R.+J.+Riley&title=Evaluation+of+human+pharmacokinetics%2C+therapeutic+dose+and+exposure+predictions+using+marketed+oral+drugs&doi=10.2174%2F138920007780866799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span></div><div class="casAuthors">McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-479</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this article approaches to predict human pharmacokinetics (PK) are discussed and the capability of the exemplified methodologies to est. individual PK parameters and therapeutic dose for a set of marketed oral drugs has been assessed.  For a set of 63 drugs where the min. efficacious concn. (MEC) and human PK were known, the clin. dose was shown to be well predicted or in some cases over-estd. using a simple one-compartment oral PK model.  For a subset of these drugs, in vitro potency against the primary human targets was gathered, and compared to the obsd. MEC.  When cor. for plasma protein binding, the MEC of the majority of compds. was ≤ 3 fold over the resp. in vitro target potency value.  A series of in vitro and in vivo expts. were conducted to predict the human PK parameters.  Metabolic clearance was generally predicted well from human hepatocytes.  Interestingly, for this compd. set, allometry or glomerular filtration rate (GFR) ratio methods appeared to be applicable for renal CL even where CLrenal > GFR.  For ∼90% of compds. studied, the predicted CL using in vitro-in vivo (IVIV) extrapolation together with a CLrenal est., where appropriate, was within 2-fold of that obsd. clin.  Encouragingly vol. of distribution at steady state (Vss) estd. in preclin. species (rat and dog) when cor. for plasma protein binding, predicted human Vss successfully on the majority of occasions - 73% of compds. within 2-fold.  In this lab., absorption estd. from oral rat PK studies was lower than the obsd. human absorption for most drugs, even when soly. and permeability appeared not to be limiting.  Preliminary data indicate absorption in the dog may be more representative of human for compds. absorbed via the transcellular pathway.  Using predicted PK and MEC values estd. from in vitro potency assays there was a good correlation between predicted and obsd. dose.  This anal. suggests that for oral therapies, human PK parameters and clin. dose can be estd. from a consideration of data obtained from in vitro screens using human derived material and in vivo animal studies.  The benefits and limitations of this holistic approach to PK and dose prediction within the drug discovery process are exemplified and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdbfKDFLO_UrVg90H21EOLACvtfcHk0ljnJ-GYPeJ8pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D&md5=765bdc4b870b660e813e36ae3719ddb5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F138920007780866799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866799%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DCollington%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520human%2520pharmacokinetics%252C%2520therapeutic%2520dose%2520and%2520exposure%2520predictions%2520using%2520marketed%2520oral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D463%26epage%3D479%26doi%3D10.2174%2F138920007780866799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0li8UlTCocXHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen activated protein kinases</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+Mckayauthor=P.+Martinauthor=S.+Steeleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen+activated+protein+kinases&doi=10.1158%2F1535-7163.MCT-07-0231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0li8UlTCocXHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMckay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DSteele%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen%2520activated%2520protein%2520kinases%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2209%26epage%3D2219%26doi%3D10.1158%2F1535-7163.MCT-07-0231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ward, R. A.; Graham, M. A.; Swallow, S.; Jones, C. D.</span>; <span> </span><span class="NLM_article-title">Substituted 3,4-dihydropyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one derivatives as kinase inhibitors</span>. PCT Int. Appl. WO2016162325A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+A.+Ward&author=M.+A.+Graham&author=S.+Swallow&author=C.+D.+Jones&title=Substituted+3%2C4-dihydropyrrolo%5B1%2C2-a%5Dpyrazin-1%282H%29-one+derivatives+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DSubstituted%25203%252C4-dihydropyrrolo%255B1%252C2-a%255Dpyrazin-1%25282H%2529-one%2520derivatives%2520as%2520kinase%2520inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomason, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkley, T. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trueman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouchet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaheen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumberbatch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaughan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span> </span><span class="NLM_article-title">AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1727</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=10.1158%2F1535-7163.MCT-12-1174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=23861347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1715-1727&author=S.+A.+Loddickauthor=S.+J.+Rossauthor=A.+G.+Thomasonauthor=D.+M.+Robinsonauthor=G.+E.+Walkerauthor=T.+P.+J.+Dunkleyauthor=S.+R.+Braveauthor=N.+Broadbentauthor=N.+C.+Strattonauthor=D.+Truemanauthor=E.+Mouchetauthor=F.+S.+Shaheenauthor=V.+N.+Jacobsauthor=M.+Cumberbatchauthor=J.+Wilsonauthor=R.+D.+O.+Jonesauthor=R.+H.+Bradburyauthor=A.+Rabowauthor=L.+Gaughanauthor=C.+Womackauthor=S.+T.+Barryauthor=C.+N.+Robsonauthor=S.+E.+Critchlowauthor=S.+R.+Wedgeauthor=A.+N.+Brooks&title=AZD3514%3A+A+small+molecule+that+modulates+androgen+receptor+signaling+and+function+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-12-1174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo</span></div><div class="casAuthors">Loddick, Sarah A.; Ross, Sarah J.; Thomason, Andrew G.; Robinson, David M.; Walker, Graeme E.; Dunkley, Tom P. J.; Brave, Sandra R.; Broadbent, Nicola; Stratton, Natalie C.; Trueman, Dawn; Mouchet, Elizabeth; Shaheen, Fadhel S.; Jacobs, Vivien N.; Cumberbatch, Marie; Wilson, Joanne; Jones, Rhys D. O.; Bradbury, Robert H.; Rabow, Alfred; Gaughan, Luke; Womack, Chris; Barry, Simon T.; Robson, Craig N.; Critchlow, Susan E.; Wedge, Stephen R.; Brooks, A. Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1715-1727</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease.  Here, we describe the biol. characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling.  AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven nuclear translocation of AR and a downregulation of receptor levels, both of which were obsd. in vitro and in vivo.  AZD3514 inhibited testosterone-driven seminal vesicle development in juvenile male rats and the growth of androgen-dependent Dunning R3327H prostate tumors in adult rats.  Furthermore, this class of compd. showed antitumor activity in the HID28 mouse model of CRPC in vivo.  AZD3514 is currently in phase I clin. evaluation.  Mol Cancer Ther; 12(9); 1715-27. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUjB28XcSVrVg90H21EOLACvtfcHk0ljzGIEfLcmxCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI&md5=553f0953189e9e5982a08c7933566ce0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1174%26sid%3Dliteratum%253Aachs%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DRobinson%26aufirst%3DD.%2BM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DDunkley%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DShaheen%26aufirst%3DF.%2BS.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DWomack%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26atitle%3DAZD3514%253A%2520A%2520small%2520molecule%2520that%2520modulates%2520androgen%2520receptor%2520signaling%2520and%2520function%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1715%26epage%3D1727%26doi%3D10.1158%2F1535-7163.MCT-12-1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NGU','PDB','5NGU'); return false;">PDB: 5NGU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I60" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I60','PDB','3I60'); return false;">PDB: 3I60</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHF','PDB','5NHF'); return false;">PDB: 5NHF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHH','PDB','5NHH'); return false;">PDB: 5NHH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHJ','PDB','5NHJ'); return false;">PDB: 5NHJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHL','PDB','5NHL'); return false;">PDB: 5NHL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHO','PDB','5NHO'); return false;">PDB: 5NHO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP','PDB','5NHP'); return false;">PDB: 5NHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHV','PDB','5NHV'); return false;">PDB: 5NHV</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00267">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_64457"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00267">10.1021/acs.jmedchem.7b00267</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional data analyses, experimental information, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_001.pdf">jm7b00267_si_001.pdf (972.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00267/suppl_file/jm7b00267_si_002.csv">jm7b00267_si_002.csv (1.72 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00267%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-8%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00267" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a8fa52b77223c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
